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ABSTRACT  
Immunohistochemical Analysis of a Panel of Human and Murine Markers on 
Xenografted Human Vaginal Mucosa: A Comparative Study 
W. Bingham 
MSc Thesis, Department of Medical Biosciences, University of the Western Cape 
 
Athymic nude mouse models have been extensively used to study biological behaviour of 
normal and diseased human tissues. In such models, immune-deficient mice act as hosts for 
cysts constructed from human material. A unique biocyst model that entails transplantation of 
human vaginal cysts into athymic nude mice has been implemented to study diseases of oral 
mucosa. To date, only one immunohistochemical study of this biocyst model has been 
reported. Nevertheless, conclusions made in that study were only based on the observed 
expression patterns of human and murine markers. Statistical assessment of 
immunohistochemical data had been omitted by the investigator. Therefore, the objective of 
this study was to further delineate the immunohistochemical profile of normal human vaginal 
tissue and human vaginal tissue that had been xenografted into nude mice. 
Experimental cysts constructed from human vaginal mucosa were xenografted into athymic 
nude mice and harvested 9-weeks post transplantation. Immunohistochemical analysis of 
normal human vaginal tissue and human vaginal tissue that had been xenografted into nude 
mice was performed using a panel of human and murine markers. Expression patterns of 
human and murine markers were assessed. Human markers included cytokeratin 1, 
cytokeratin 5, cytokeratin 13, cytokeratin 14, collagen type IV, laminin, elastin, fibronectin, 
Langerhans cells and VEGFR-3. Murine markers included collagen type IV, laminin, 
 
 
 
 
iv 
fibronectin, Langerhans cells and VEGFR-2. Staining intensities were quantified and 
statistically analysed using one-way ANOVA with subsequent Friedman’s test for multiple 
comparisons. Since the sample size was small, the power of the test statistic was enhanced by 
including Dunn’s post-test for further multiple comparisons.  
A strong positive expression of all cytokeratins was detected in both normal and xenografted 
vaginal tissues. Human markers that exhibited weak to moderate positive expression were 
collagen IV, laminin, fibronectin and VEGFR-3. Human elastin and human Langerhans cells 
exhibited strong and varying expression patterns respectively. Weak expression patterns for 
all murine markers were reported, with an exception of VEGFR-2 which was negatively 
expressed in all xenografted vaginal tissues. Significant differences (P<0.05) in the mean 
staining intensities between normal and xenografted vaginal tissues were reported for 
cytokeratin 1, fibronectin and Langerhans cells. There were no statistical differences (P>0.05) 
in the mean staining intensities for other markers. 
In conclusion, immunohistochemical studies proved that human vaginal tissue could not only 
survive in nude mice, but could also become active and develop structures necessary for 
survival, in this case, a newly formed stromal layer. The epithelium and stromal layer 
exhibited a human ecosystem. 
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CHAPTER ONE 
INTRODUCTION 
1.1 BACKGROUND  
Animal models have been extensively used to identify clinically efficacious agents of various 
human disorders. Amongst these models is the athymic nude (nu/nu) mouse model. The 
discovery of athymic nude mice has led to effective transplantation and propagation of 
various human tissues and cell lines into mice [1-3]. On the contrary, the predictive value of 
these athymic nude mouse models still remains a subject of controversial debate. 
Thompson et al., [4] implemented a biocyst model in which human vaginal epithelium was 
used to construct cysts which were then transplanted into athymic nude mice. They proposed 
this model as an in vivo biotest system to study oral mucosal disorders in humans [4]. 
Moreover, they hypothesized that the epithelium of the cyst remains unchanged after 
transplantation into immune-deficient mice. Thompson et al., [4] established that allowing 
cysts to remain in mice for 9-weeks was an ample period to allow integration of cysts into a 
murine environment. Nevertheless, Thompson and colleagues’ work was not entirely 
successful due to infection incurred by the cysts. Further investigation of this remarkable 
model was therefore undertaken by Wang and Hille [5]. They identified possible sources of 
infection that had initially affected the integrity of the experimental cysts. With stringent 
infection control measures, Wang and Hille obtained intact cysts 9-weeks post 
transplantation. They presented evidence that the structure of the epithelium remained 
unchanged, thus confirming the hypothesis made by Thompson et al., [4]. Although Wang 
and Hille refined Thompson’s cyst model, immunohistochemical profiling of the transplanted 
epithelial cysts remained unknown. For that reason, Kok [6] undertook a study in which he 
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characterized and compared normal human vaginal mucosa and transplanted epithelial cysts. 
The study entailed histological and immunohistochemical profiling of normal vaginal tissues 
and transplanted experimental cysts [6]. Kok’s immunohistochemical data had not been 
statistically assessed. Therefore, conclusions made were based on the observed expression 
patterns of human and murine markers. 
To the best of our knowledge, Kok’s study of this biocyst model is the only one with 
relatively extensive immunohistochemical results. We therefore undertook this study in an 
attempt to reassess the immunohistochemical profile of normal vaginal tissues in comparison 
to xenografted vaginal tissues. To clarify the discussion of the comparative results, our study, 
incorporates for the first time, statistical assessment of the staining intensities of human and 
murine markers. We attempted to elucidate the nature of the epithelium, the basement 
membrane and stromal layer of the xenografted tissue based, not only on the expression 
patterns of markers, but also on the level of statistical significance. 
1.2 RATIONALE 
Human vaginal mucosa serves as a portal for various micro-organisms, including those that 
are pathogenic. The penetration of human vaginal mucosa by micro-organisms often leads to 
infections. Some of the infections are strongly associated with the development of carcinoma 
of the cervix, vagina and vulva. Carcinoma of the cervix, ovaries and vagina affect a 
significant number of women worldwide, with approximately 80, 720 cases reported 
annually, with an estimated mortality rate of 28, 120 women per year [7]. Advances in 
surgery and chemotherapy have improved survival for carcinomas, but such improvements 
have not been that remarkable [7]. Several researchers rely on athymic nude mouse models to 
study carcinomas [2, 8], and to establish diagnostic and therapeutic modalities [8]. This study 
is imperative in that it provides information about the morphology of human vaginal mucosa 
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that had been xenografted into athymic nude mice. It is hoped that information obtained from 
this study will facilitate future research application, particularly in cases where mice models 
are used to identify efficacious agents for various infections. 
1.3 PURPOSE OF THE STUDY 
1.3.1 Aim 
The aim of this study was to analyze and compare morphological characteristics of normal 
human vaginal mucosa and human vaginal mucosa that had been xenografted into athymic 
nude mice. 
1.3.2 Objectives 
 Firstly, we used immunohistochemistry to investigate expression profiles of 
cytokeratin 1, 5, 13 and 14, collagen type IV, laminin, elastin, fibronectin, Langerhans 
cells,VEGFR-2 and VEGFR-3 in normal vaginal tissues and xenografted vaginal 
tissues. 
 Based on the outcome of the first objective, the staining intensity of all vaginal tissues 
was assessed semi-quantitatively and scored according to a specified scoring system. 
 Staining intensities reported were statistically compared. Staining intensities reported 
by Kok were also included in statistical tests. 
 The nature of the epithelium, basement membrane and stromal layer were ultimately 
determined based on the expression patterns of human and mouse markers as well as 
on statistical data. 
1.3.3 Research Question 
The research question was, ‘Are morphological characteristics of human vaginal tissue 
retained after transplantation into athymic nude mice?’ 
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1.4 RESEARCH METHODOLOGY 
The study was undertaken in an academic research environment at the University of 
Stellenbosch and the University of the Western Cape. An experimental prospective research 
design consisting of two phases was used. The first phase involved preparation of human 
vaginal tissues whereas the second phase entailed immunohistochemical profiling of human 
vaginal tissues. In the first phase, cysts were constructed from human vaginal mucosae, 
xenografted into athymic nude mice and retrieved 9-weeks post transplantation. In the second 
phase, expression patterns of human and murine markers were investigated 
immunohistochemically. Tissue sections were then scored according to a semi quantitative 
scoring system. Mean staining intensities of normal and xenografted vaginal tissues were 
statistically analyzed using GraphPad Prism 5.0 (GraphPad Software, Inc). 
1.5 ORGANIZATION OF CHAPTERS 
 Chapter 1 – Introduction 
 Chapter 2 – Literature Review 
 Chapter 3 – Materials and Methods 
 Chapter 4 – Results 
 Chapter 5 – Discussion and Conclusion 
 Chapter 6 – Limitations of the Study and Future Prospects 
1.6 CONCLUDING REMARKS 
Chapter 1 gave an overview of the research project. The background, aim and objectives as 
well as the significance of the project were outlined to present the rationale of conducting this 
study. Chapter 2 will review the literature of human vaginal mucosa and athymic nude mouse 
models. The markers under investigation and immunohistochemistry will also be reviewed in 
the next chapter. 
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CHAPTER TWO 
LITERATURE REVIEW 
Human vaginal mucosa is the first part of the female genital tract that encounters commensal 
bacteria and pathogenic micro-organisms [9]. Knowledge of the histological distribution of 
proteins in the extracellular-matrix (ECM) of human vaginal mucosa is scarce, although a 
better understanding of this may lead to improved protection of vaginal mucosa. Moreover, 
for several decades, the laboratory mouse has been the primary species in which experimental 
treatments for various conditions have been tested [1, 2, 8, 10]. However, the predictive value 
of a mouse model has been and still remains the subject of detailed investigations. This 
chapter will review human vaginal mucosa and athymic nude mice. The focus of this chapter 
will also be on some aspects of biochemistry and molecular biology of human and murine 
markers under investigation. The chapter will be concluded by briefly discussing 
immunohistochemistry, a technique that was used to analyze expression profiles of the 
markers under investigation. 
2.1 ORGANIZATION OF HUMAN VAGINAL MUCOSA 
The human vagina is a muscular tube that extends from the ectocervix to the vestibule [11]. 
The vagina serves as a conduit for menstrual flow, receives the erect penis during sexual 
intercourse and acts as a birth canal. Under normal conditions, the length of the vagina is 
approximately 6-7.5 cm across the anterior wall and 9 cm across the posterior wall. The 
vagina extends upwards and back into the pelvic cavity. It is posterior to the urinary bladder 
and urethra, anterior to the rectum and is attached to these structures by connective tissues. 
The vaginal wall comprises three layers namely, adventia, muscularis and mucosa. Adventia, 
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the outer fibrous layer, consists of a dense connective tissue interlaced with elastic fibers. 
This outer layer attaches the vagina to the surrounding organs. The middle muscular layer is 
predominantly composed of smooth muscle fibers. The inner mucosal layer consists of 
stratified squamous epithelium [12]. This layer lacks mucous glands and vaginal mucus is 
therefore provided by cervical and vestibular glands [12]. The key role of vaginal tissue is to 
provide protection from strain during copulation [13]. Since the mucosa is the subject of this 
study, its constituents, the epithelium, the basement membrane and connective tissue will be 
briefly discussed.  
2.1.1 Epithelium: A Protective Barrier 
The epithelium serves as one of the primary tissues that cover and protect the exterior surface 
and the interior cavities of the body [14]. The epithelium is classified according to certain 
characteristics such as the number of cell layers, the shape and distinct functions of the cells. 
As already stated above, the human vaginal mucosa consists of stratified squamous epithelia 
[12, 14, 15]. It is a highly flexible structure commonly referred to as non-keratinized 
epithelium and consists mainly of squamous cells [14]. The epithelium rests on both the 
lamina propria and an underlying sub-mucosa [15]. It is differentiated in a manner that allows 
it to fulfill certain demands such as protecting the underlying tissues from mechanical, 
chemical and microbial stress. The surface epithelial layers act as permeability barriers that 
regulate movement of substances across the mucosa, thereby protecting the underlying deeper 
tissues. If the barrier is compromised, then potentially lethal substances may adhere to the 
surface of the mucosa, penetrate it and induce pathologic changes which could present as 
local or systemic diseases. The permeability barrier of the epithelium is influenced by the 
composition and organization of lipids found on superficial cell layers of the tissue. This 
barrier is relatively inert due to terminally differentiated cells of the epithelium. These 
properties are factors that enable the mucosa to remain functional for extensive periods 
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during ex-vivo studies. The intermediate cell layers of the epithelia comprise small membrane 
coated granules (mcg), which extrude their contents into the intercellular space [14]. 
2.1.2 Basement Membrane: A Specialized ECM 
The extracellular matrix (ECM) is a diverse and dynamic protein network that plays a critical 
role in cell and tissue function [16-20]. Originally, the ECM was perceived as a physical 
scaffold that provides mechanical support and strength to cells and tissues [17, 18]. However, 
it has now been established that the ECM does not only promote the interaction between cells 
and tissues, but also elicits biochemical signaling [17]. Physical and chemical features of the 
ECM are essential for development and for responses to physiological and pathological 
signals [21]. 
The basement membrane (BM) is a 50-100 nm complex and highly organized layer of the 
ECM and is commonly referred to as specialized extracellular matrix (sECM) [21, 22]. BMs 
are found in every tissue of the human body [22, 23] and their formation is necessary for 
normal tissue development and function [21]. Although BMs of different tissues are 
heterogeneous [23], they all provide structural integrity and regulate vital cellular signaling 
cues from the microenvironment [21, 22, 24]. BMs separate cell monolayers from the 
underlying connective tissue [22, 24-26]. BMs are divided into lamina lucida, lamina densa 
and the sublamina densa [25, 27-29]. The lamina densa defines the electron dense region of 
the BM. This region is mainly composed of collagen and laminin networks crosslinked by 
nidogen/entactin and percelan [28]. These components are essential for BM stability [22, 28, 
30]. BM components interact with cell-surface receptors and non-integrin receptors to 
monitor biological activities which include development, proliferation, differentiation, 
growth and migration of cells [21]. A detailed discussion of the structure and roles of 
collagen IV and laminin is included in subsequent sections. 
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2.1.3 Connective Tissue: A Supportive Component 
The connective tissue is the most abundant type of tissue that binds cells which occur in 
tissues throughout the body. This fibrous tissue consists of relatively few cells which 
synthesize connective tissue matrix. Physical properties of the matrix promote functions of 
the connective tissue. Connective tissues provide mechanical support by inducing strength, 
stability, protection and tissue repair. Moreover, connective tissues provide a surface area for 
intercellular exchange. Such an exchange is critical for a continuous supply of essential 
substances and removal of waste products [31]. 
2.2 ANIMAL MODELS 
Animal models have been used extensively to study biological behavior of human tissues. 
This has led to the development of various animal models of malignant diseases. The 
majority of these models can be grouped into two. The first group which consists of grafts of 
tumor material can be categorized into immune-competent or immune-deficient animals. The 
second group consists of genetically engineered mice that replicate a specific cancer genotype 
[1]. Although these two groups both possess unique qualities, the ability of the second group 
in illustrating significant clinical activities remains unclear [1]. Since this study entails using 
immune-deficient mice, the significance of athymic nude mice will thus be briefly reviewed 
in the following sub-section. 
2.2.1 Significance of Athymic Nude Mice in the Medical World 
A nude mutant mouse was discovered more than four decades ago [2, 8, 32]. It was named 
athymic nude mouse because it lacks a functionally active thymus. A nude mouse is a timid 
and genetically odd animal that is hairless due to a single autosomal recessive gene [32, 33]. 
Since the first successful hetero-transplantation of human colonic adenocarcinoma into nude 
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mouse by Rygaard and Povlsen, several laboratories have been using these nude mice [1]. 
Athymic nude mice are therefore regarded unique due to their lack of cell-mediated immune 
response [32]. 
Athymic nude mouse (NM) model has now become an established tool to investigate the 
biology and pathophysiology of human diseases [2, 8, 32], and to develop diagnostic and 
therapeutic strategies [8]. For instance, the model allows routine and efficient transplantation 
and propagation of human tumor tissues into mice [1]. Since NMs have an ability to host 
cancer cells without rejection, the effects of therapeutic drugs or radiation are determined 
using these strains of mice [8]. In addition, it has been reported that in general, xenografts in 
NMs retain their original morphology and biology and show a high degree of genetic 
integrity. Nonetheless, in some cases, original morphology and biology is not retained. It has 
been reported that changes in cell growth and morphology of xenografts could result from 
immunological and local factors including, cell-to-cell or cell-to-matrix interactions, growth 
factors, cytokines, hormones and locally active enzymes [8]. For instance, some studies have 
demonstrated that although tumor xenografts normally retain the phenotype of the original 
tumor, the metastic potential is lost [8]. This clearly indicates that there are biological and 
morphological changes that occur when human tissues are transplanted into a murine 
environment. Therefore, if therapeutic approaches to treating conditions of the female genital 
tract using NM models are to be achieved, it is important to determine which morphological 
properties of human vaginal tissues change after transplantation into NMs. 
2.3 CYTOKERATINS 
Cytokeratin (CK) is a cytoskeletal intermediate filament protein expressed in various human 
epithelial cells. The expression of CKs is specific for each epithelial cell type. At least 20 CK 
subtypes are known with molecular weight ranging from 40 to 70 kD. Acidic type I CKs are 
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designated CK9 to CK19 whereas Basic Type II CKs are designated CK1 to CK8 [34, 35]. It 
has been reported that CKs are involved in the formation of cellular frameworks and can 
serve as markers of malignancies associated with the epithelium [36]. 
2.4 COLLAGEN TYPE IV 
Collagens constitute 30% of the total protein mass in humans, which makes collagens the 
main components of the ECM. Predominantly expressed collagen types include interstitial 
matrix type I and basement membrane type IV [17]. This section provides a brief overview of 
the structure and expression of collagen. The involvement of collagen IV in BM assembly is 
also summarized. 
2.4.1 The α-Chains of Collagen IV 
Type IV collagen is a non-fibrillar collagen that constitutes approximately 50% of all BMs 
[22, 37, 38]. Studies have shown that non-fibrillar collagen occurs at embryonic stage day 4.5 
(E4.5) in mice. Non-fibrillar collagens can be distinguished from connective tissue fibrillar 
collagens by the presence of globular non-collagenous (NC) domains [22]. Collagen IV 
consists of six distinct chains referred to as α-chains (α1-α6) [21, 22, 39, 40]. Each α-chain is 
400 nm long and consists of three domains namely, Amino (N)-terminal 7S domain, triple 
collagenous domain and carboxyl (C)-terminal non-collagenous (NC) globular domain [22, 
41]. The triple collagenous domain has repetitive Gly-X-Y amino acid sequence where X and 
Y represent proline and hydroxyproline respectively. The sequence of amino acids is crucial 
for structural integrity of collagen IV protomer and suprastructure. Short sequence 
interruptions of the collagenous domain provide a sufficient degree of flexibility. The 7S and 
NC1 domains are essential for type IV collagen network formation [22]. Although the six α-
chains are homologous, their NC1 domains are not the same. Cells secrete Type IV collagen 
as protomers [22], which are essentially three distinct heterotrimers termed α1α1α2, α3α4α5 
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and α5α5α6 [21, 22]. Protomers serve as the building blocks of type IV collagen networks 
[22]. Assembled protomers are distributed on tissues in a specific manner and ultimately 
define the structure and function BMs [21]. 
2.4.2 Expression and Interaction of Collagen IV 
Collagen IV exists as α1α1α2 heterotrimer during development [21], where it is evenly 
distributed in BMs [17, 21, 42].  However, during maturation, the α1α1α2 heterotrimer gets 
partially displaced by another heterotrimer such as α3α4α5. This has been observed in the 
kidney glomeruli, the skin, oesophagus and smooth muscle cells [21]. Mechanical stability of 
BMs is mainly influenced by collagen IV scaffold [3, 21, 43, 44]. This protein provides 
mechanical support to tissues and is actively involved in tissue function [45]. Collagen IV 
interacts with various cells including platelets, hepatocytes, hepatocytes, and keratinocytes. 
Endothelial cells (ECs), pancreatic cells as well as tumor cells have also been reported to 
interact with collagen IV. Collagen IV interactions are regulated by integrins and non-
integrin receptors. Integrins that have been identified in collagen IV interactions include 
α1β1, α2β1, α3β1, α6β1, α10β1, α11β1, αvβ3, and αvβ5. Non-integrin receptors that have 
been reported in such interactions include CD44 and discoidin domain receptor-1 (DDR-1). 
Moreover, it has been indicated that DDR-1-collagen IV interactions are critical for the 
structural integrity and filtration function of BMs in the kidney [21]. 
2.4.3 Collagen IV Assembly 
Self-assembly of collagen IV suprastructure is responsible for BM assembly [22]. Collagen 
IV together with laminin are enmeshed to form the basic framework of BMs. Protomers and 
NC1 domains, which induce triple helix formation are both formed in the Golgi apparatus. 
These protomers are then secreted and self-assembled into collagen IV suprastructure. Four 
protomers interact through their 7S domains which are then covalently stabilized. This 
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interaction has been shown to have a structure that resembles a ‘spider shape’. In addition, 
two protomers interact through NC1 trimers to form NC1 hexamer, which is also stabilized 
by a covalent bond. Both these types of protomer interaction establish a unique scaffold 
which plays a critical role in the formation of BMs [22]. 
2.5 LAMININ 
The laminin family of glycoproteins was first discovered as a product of mouse Engelbreth-
Holm Swarm (EHS) sarcoma cells almost three decades ago [18, 27, 28]. This non-
collageneous glycoprotein is significantly implicated in various biological activities such as 
BM assembly and regulation of cellular differentiation, adhesion and migration [28, 46]. In 
this section, the structure and distribution of laminin as well as the role it plays in BM 
formation and tumor invasion shall be briefly explored. 
2.5.1 Family of Laminin Glycoproteins 
Laminins are extracellular heterotrimeric glycoproteins composed of different combinations 
of chains designated α-, β-, and γ-chains [18, 21, 22, 28, 30, 47, 48], depending on sequence 
identity and protein domain organization [22]. These large molecules are 400-900 kDa in 
weight and exhibit a cross-like structure [28, 48]. To date, five α, four β, and three γ chains 
[28, 47-49], including splice variants [28] have been identified. In vertebrates, these subunits 
assemble into at least sixteen laminin isoforms termed laminin 1-15 [21, 28, 48]. Each 
laminin chain is composed of rodlike, globular and coiled regions. The separate chains are 
linked by disulphide bonds at the coiled coil regions. The 400 kDa α-chain is the largest [22, 
28], and comprises of long and short arms at the carboxyl-terminal and amino-terminal ends 
respectively. The C-terminal end of the long arm consists of domains named LG 1-5 [28]. 
The β- and the γ-chains are approximately 200 kDa and differ from the α-chain by the 
absence of the G domains [22]. The C-terminal end of the α-chain interacts with integrin 
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receptors and dystroglycans. Moreover, the N-terminal end also binds to integrin receptors, 
although it is more implicated in laminin polymerization. The β and γ chains associate with 
other components of the ECM [28]. 
Table 2.1: Functional Domains of Laminin 
 
Adapted from [50] 
 
2.5.2 Tissue Distribution of Laminin Isoforms and Receptors 
Laminin, one of the major constituents of the BM [51-54] has been implicated in various 
ECM-regulated activities. Such activities include interaction with epithelial cells, stimulation 
and maintenance of tumor initiation and development [49]. All 15 laminin isoforms are 
constituents of BMs. Expression patterns of laminin isoforms are modulated both temporally 
and spatially within organisms [28]. This leads to distinct distribution of the different laminin 
isoforms during development and in adult tissues [21, 22, 28, 48]. Therefore the laminin 
isoforms fulfill precise key roles in modulating tissue structure and cell behavior [21, 28, 48]. 
Laminin 1 (111), the isoform that was first identified during development at E4.5 in mice, is 
the highly expressed type in the BM [22, 46]. Laminin-111 and laminin-511 are the main 
isoforms essential for embryonic development, whereas other isoforms are implicated during 
organ maturation and specific tissue functions [21]. The α1 chain, present in laminin 1 (111) 
and 3 (121), is highly expressed in epithelial cells during early embryogenesis. Its expression 
becomes more restricted during development and is then only found in adult reproductive 
organs, kidney and liver [28]. Laminin-111 has also been found in the chondrocytes of 
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healthy human cartilage [21]. Laminins 2 (211), 4 (221) and 12 (213) consist of the α2, which 
is mostly expressed in the neuromuscular system [21, 28], where they coordinate postsynaptic 
and presynaptic maturation [21]. The α3 chain, found in laminins 5 (332), 6 (311), and 7 
(321), is localized to the skin and other epithelia. Laminin-332 plays a significant role in skin 
function. Furthermore, expression of this isoform has been observed in embryonic cartilage 
[21]. The α4 chain, found in laminins 8 (411), 9 (421), and 14 (423), is expressed in cells of 
mesenchymal origin. Laminin 8 together with laminin 10 (511), 11 (521) and 15 (523) are 
readily expressed throughout the body in adult epithelial, neuromuscular, and vascular tissues 
[28].  
2.5.3 The Interaction of Laminin with Cell Surface Receptors 
Integrins and non-integrin molecules are some of the major laminin cell surface receptors [28, 
53]. More than eight integrins that have been identified include α1β1, α2β1, α5v1, α3β1, 
α6β1, α6β4, αvβ3, αvβ5 and α7β1 [28]. Each integrin is sequence-specific and thus 
recognizes and interacts with a specific set of isoforms. The recognition site located on the 
integrin receptor is formed by the combination  of its α- and β-chains [28]. The G-domain at 
the C-terminal end serves as the major site for laminin cell adhesion [22]. Therefore, laminin-
integrin interaction occurs substantially at the C-terminal end of the α-chain. However, such 
an interaction can also occur at the N-terminal end. The β- and γ-chains can also partake in 
laminin-integrin interaction [28]. Some of laminin interactions include α-dystroglycan with 
laminin α1 and α2 chains and the Lutheran blood group glycoprotein which interacts 
exclusively with laminin α5 chains [21]. Non-integrin cellular receptors for laminins include 
syndecans [21] and heparin sulphate proteoglycans [28]. Interaction of laminin with non-
integrin receptors also occurs at the C-terminal of the α-chain [28]. 
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2.5.4 Prominent Role of Laminins: Basement Membrane Assembly 
Laminins play a critical role in providing structure to the ECM and adhesion of cells to the 
BM [22, 55, 56]. It has now been established that the precise manner in which alpha subunits 
interact with integrins or non-integrin receptors is essential for the self-assembly and 
polymerization of laminin networks [21]. This network assembling of laminin heterotrimeric 
laminins into oligomers is necessary for BM formation [21, 22, 57]. As already stated, the 
scaffold of enmeshed laminin and type IV collagen networks is the basic framework of BMs 
[22, 54, 58]. In the Golgi apparatus, ionic interactions enhance βγ dimer formation, which is 
subsequently stabilized and secreted when the α-chain is included. Disulfide bridges provide 
stability for the three chains at their intersection point, thereby allowing laminin to self-
assemble into a honeycomb-like polymer. The mechanism of self-assembly still remains 
elusive, but it appears to be calcium dependent and associated to the globular domain VI of 
each chain. It has also been proposed that the three-arm interaction model for laminin 
polymer self-assembly could be responsible for the honeycomb network [22, 28]. 
2.5.5 The Role of Laminin in Pathology: Tumor Invasion 
Under physiological or pathological states, the ECM houses laminin fragments that are 
unable to polymerize into networks, consequently promoting cell migration as has been 
illustrated by laminin-332 [21]. Laminin 332 has been reported to partake in cell migration, 
and it has hence been implicated in tumor invasion [28, 50]. Highly expressed laminin γ2-
chain has been noted in many epithelial human cancers such as lung and colon cancers. This 
high expression level of γ2-chain, particularly at the leading edges has been linked to cancer 
invasiveness. Moreover, the detection of this chain has been proposed to serve clinical 
diagnostic and prognostic purposes. Most of the γ2 chains that were detected in tumor cells 
were positioned in the cytoplasm [28]. 
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2.6 ELASTIN 
Tissue flexibility and extensibility are critical properties in multicellular organisms [59]. 
Elastic fibers, the insoluble macromolecules of the ECM, are the key components of 
connective tissues [60, 61]. Elastic fibers provide resilience to connective tissues, which aids 
in long-range deformability. Moreover, passive-elastic recoil of connective tissues is another 
property provided by elastic fibers [59, 62]. These properties are essential for the long-term 
function of different forms of tissues. Elastic fibers comprise two morphologically and 
chemically distinct constituents namely elastin and microfibrils. About 90% of the fiber is 
constituted by elastin [62-64] which is on the internal core and is enclosed by microfibrils 
[59, 62]. The structure of elastin, with particular focus on the events that lead to formation of 
elastin are described in this section.  
2.6.1 Elastin: A Protein Synthesized from Tropoelastin 
Elastin is a chemically inert, highly insoluble polymer synthesized from a precursor molecule 
tropoelastin [60, 62, 63, 65]. Tropoelastin, a soluble, non-glycosylated and hydrophobic 
protein provides stability to elastin through its covalently cross-linked molecules. 
Tropoelastin is about 60-70 kDa and can exist as either an open globular molecule or a 
distended polypeptide [62]. Expression of this precursor molecule with subsequent elastin 
formation appears in fibroblast, vascular smooth muscles cells, endothelial cells and 
chondrocytes [63]. Elastin is classified as a major ECM tissue protein that is critically 
involved in tissue elasticity and resilience [62, 63, 65, 66].  
2.6.2 Structural Properties of Elastin 
Several studies have been undertaken to establish structural properties of soluble elastin, 
however, a consensus has not yet been attained. Macroscopically, elastin appears as a pale 
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yellow amorphous mass. Transmission electron and atomic force microscopy (TEM and 
AFM) studies have indicated that elastin is a fibrillar substructure composed of 
approximately 5nm thick filaments that are parallel-aligned and resemble a twisted rope. 
Circular dichroism (CD) is another study that has been done to illustrate that human 
tropoelastin consists of 3% α-helix, 41% β-sheet, 21% β-turn and 33% of other structures 
[62]. 
2.6.3 Elastogenesis: From Tropoelastin to Elastic Fibers 
Formation of elastic fibers is a highly organized process that entails a chain of events. The 
interaction of microfibrils and tropoelastin during formation of elastic fibers is a process 
limited to foetal and early neonatal development [64]. These critical events include control of 
intracellular transcription and translation of tropoelastin, intracellular processing and 
secretion of the protein into the ECM. Moreover, the transport and alignment of tropoelastin 
at elastogenesis sites and conversion of tropoelastin to insoluble elastin polymer form part of 
elastogenesis events [62]. The process of elastogenesis is summarized in Figure 2.2. 
 
Figure 2.1: Classical Model of Elastogenesis. Tropoelastin is transcribed from a single gene and alternatively 
spliced in the nucleus. (A) Subsequent to translation and signal sequence cleavage, tropoelastin associates with 
EBP and FKBP65 in the rough endoplasmic reticulum. The tropoelastin-EBP complex then moves through the 
Golgi and gets secreted to the cell surface. (B) Secreted tropelastin gets oxidized by a lysyl oxidase family 
member and tropoelastin associates with microfibrils and other tropoelastin molecules through coacervation to 
generate the nascent elastic fiber. (C) Continued secretion, oxidation and deposition of tropoelastin occupy the 
bulk of elastin synthesis. EBP-elastin binding protein; FKBP65-65-kDa FK506 binding protein; MAGP-
microfibril associated glycoprotein; LTBP-latent transforming growth factor β-binding protein; MFAP-
microfibril associated protein; LOXL-lysyl oxidase like. Source: [62]. 
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2.7 FIBRONECTIN 
Fibronectin (FN) is a complex glycoprotein associated with cellular interactions which 
involve inter-communication between cells and the extracellular material [67]. The active 
form of FN is an elongated protein assembled into an insoluble fibril [68]. The transformation 
of the FN molecule into a fibril is an extensively regulated cell-mediated process [68]. This 
section details biological and structural characteristics of fibronectin. The role fibronetin 
plays in cellular interactions and in tumorigenesis is also outlined. 
2.7.1 Fibronectin: Brief Overview 
Fibronectin is widely expressed by multiple cell types and it has been demonstrated that it is 
essential for development in vertebrates. Evidence of this has been provided in studies in 
which inactivation of the FN gene resulted in early embryonic lethality of mice [69]. This 
major ECM protein exists as an asymmetric dimer consisting of two identical subunits of 
approximately 250 kDa. These subunits are covalently bonded at a region close to the 
carboxyl-terminus by a pair of disulfide bonds [67-70]. Each monomer consists of three types 
of repeating units named type I, type II and type III [68-70]. The FN molecule contains 12; 2 
and about 15 type I, type II and type III repeats, respectively. These repeats contribute to 
approximately 90% of the FN sequence [69]. Although FN molecules are derived from a 
single gene, the resulting protein can exist in multiple forms that arise from alternative 
splicing of a single pre-mRNA that can yield as many as 20 variants in human FN [68, 69]. 
2.7.2 Fibronectin: Constituent of the Plasma and the ECM 
FN is an abundant soluble constituent of the plasma (300 µg/ml) and other body fluids. It also 
forms an insoluble constituent of the ECM [67, 69]. Moreover, the molecule is also scattered 
in the juxtacanalicular tissue (JCT) and in the trabecular beams [68]. Although FNs can be 
synthesized by a vast number of cells in vitro, fibroblasts and ECs appear to be the major 
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producers. Apart from fibroblasts and ECs, FNs can also be synthesized by chondrocytes, 
myoblasts, macrophages, hepatocytes, epithelial and amniotic cells [67]. Based on solubility 
traits, two types of FN termed plasma (pFN) and cellular (cFN) FNs have been identified. 
pFN exists as a soluble protein whereas cFN is a less-soluble form [67, 69, 70], that has the 
appearance of fibrillar extracellular matrix [69]. Although pFN and cFN can be distinguished, 
they have structural similarities [67]. pFN is synthesized predominantly in the liver by 
hepatocytes [67, 69], although ECs and macrophages could also contribute given their close 
association with the bloodstream [67]. Glucose, glucocorticoids, ascorbic acid and 
transforming growth factor beta-2 (TGF-β2) are some of the factors that regulate FN 
expression in the trabecular meshwork (TM). TGF-β2 also enhances cross-linking of FN to 
itself and the surrounding ECM through action of tissue transglutaminase. TGF-FN complex 
is resistant to degradation, and thus, self-cross-linking of FN may stimulate deposition and 
retention of FN in the ECM [68]. 
2.7.3 Fibronectin: A Mediator of Cellular Interactions 
FNs have been implicated in a wide variety of cellular interactions with the ECM. Such 
interactions include cellular adhesion and morphology [18, 55, 67, 69, 70], cytoskeletal 
organization, cell migration, embryonic differentiation, oncogenic transformation, 
phagocytosis, chemotaxis and hemostasis or thrombosis [67]. Some of these cellular 
interactions are discussed below. 
The adhesion of FNs to solid substrates is the most basic role of FNs that has been 
extensively studied [67]. Numerous studies have indicated that FNs promote the adhesion and 
spreading of cells to a variety of materials including plastic, collagen, gelatin, and fibrin [67, 
69]. Cells that synthesize less or no FN often require additional exogenous FN to enhance 
adhesion and spreading. Inadequate synthesis of FN by these cells often results from their 
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oncogenic transformation. Concomitant with the spreading induced by an addition of FN, 
cells usually acquire highly ordered intracellular microfilament bundles [67]. The role of FN 
in phagocytosis was initially suggested on the basis of in vivo results which indicated that 
there is an association between the levels of pFN and the ability of an organism to clear 
unwanted material from the circulatory system. It was suggested that FN operates as a ‘non-
specific opsonin’ for thereticulo-endothelial system. This became even more intriguing when 
it became apparent that FN has a binding affinity for certain bacteria such as Staphylococcus 
aureus. Data from in vitro studies also presented evidence that FN stimulates phagocytosis of 
gelatin-coated beads by certain macrophages although heparin is required as a cofactor [67]. 
Hemostasis and thrombosis are additional biological processes that particularly involve pFN. 
FN is also involved in the regulation of several pathways. It has been reported that FN 
induces myogenesis and inhibits myoblast fusion, chondrogenesis and melanogenesis. In 
addition to this, FN has also been reported to stimulate adrenergic differentiation in explanted 
neural crest cells [67]. Extensive literature from other cell types suggests that FN and its 
receptors provide mechanical support for cell attachment and mediate a wide variety of 
biological processes that entail regulation of outflow resistance, including matrix production, 
ECM turnover, gene expression, growth factor signaling and cytoskeletal organization. 
Moreover, FN and its receptors regulate cellular mechano-responsiveness to physical forces 
such as stretch [68]. 
2.7.4 Functional Domains of Fibronectin 
The most important characteristic of FN is its ability to precisely interact with a wide variety 
of macromolecules. The best-established interactions which have been reported are the 
interactions with gelatin, collagens, fibrin, heparin and proteoglycans [67]. The ability of this 
molecule to perform so many functions is chiefly due to their flexible structure and functional 
domains [67, 68]. It has been shown that polypeptide regions of FNs are somewhat 
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susceptible to attack by a number of proteases. Such proteases cleave these polypeptide 
regions to generate separate, structured domains. composed of specific ligand binding sites 
[67]. The domains are briefly summarized below. 
2.7.4.1 Collagen-Binding Domain 
The first FN domain to be isolated was collagen-binding domain. This FN region is 
approximately 30-40000 daltons [67] and is composed of repeats I and II [69]. This region 
can be produced from digestion of an intact FN with chymotrypsin, subtilisin, thermolysin or 
pronase. Although this region is still unable to mediate cell interactions, it does interact with 
collagen or gelatin affinity columns [67]. Interestingly, such interactions are more effective 
with denatured collagen (gelatin) than are with native collagen. The presence of collagen-
triple helix appears to play a significant role in FN-collagen interactions [69]. In addition, 
larger fragments can be generated under various proteolytic conditions which allow mapping 
of the domain close to the amino-terminus [67]. 
2.7.4.2 Cell-Binding Domain 
This cell-binding region can be generated from other FN fragments that do not bind to 
collagen affinity columns. This domain exists for provision of other cell-binding activities. 
The region has the ability to mediate interaction between cells and collagen. A fragment of 15 
000 daltons still retains a significant amount of the cell-binding activity of the intact FN, but 
does not allow either collagen or heparin binding [67]. 
2.7.4.3 Fibrin and Transglutaminase Interaction Sites 
FN is also composed of two major fibrin-binding sites termed fibrin I and fibrin II [69]. The 
major site is located at the N-terminal domain and it is generated from type I, type 4 and type 
5 repeats. The interaction of FN with fibrin is essential for cell adhesion or cell migration into 
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fibrin clots [69]. Initial stages of wound healing may therefore require binding of FN to fibrin 
from blood [67].  
2.7.4.4 Glycosaminoglycan-Binding Domain 
The binding of FN to heparin and heparin-sulphate is involved in the uptake of foreign 
substances by macrophages and in structural organization of the ECM. In vitro studies have 
indicated the complex nature of FN-heparin interactions with more than two constituents of 
moderate binding affinity. The molecule can have either two or three distinct regions that 
bind to heparin. One binding site is located in the FN amino-terminal domain. A second 
binding site is located near the C-terminus of the molecule. The presence of these multiple 
heparin-binding domains with their respective sensitivities to divalent cations and salt 
concentrations indicates that FN interactions are indeed complex [67]. 
2.7.4.5 Disulfides and Sulfhydryls 
Analysis of FN fragments has indicated that its subunits are bound by inter-chain disulfides 
and are located near the carboxyl terminus of the molecule. Both the amino-terminal and the 
collagen-binding domains have a high degree of intra-chain disulfides. The amino-terminal 
domain has roughly 10% half cysteine and possibly 10 intra-chain disulfides. The intra-chain 
disulfides may be liable for the compact protease-resistant structure of this domain. The intra-
chain disulfides of the collagen-binding domain are vital for collagen binding. In addition, 
every FN subunit is composed of more than one sulfhydryl group with one group located 
approximately 170 000 daltons from the amino-terminus and the other close to the carboxyl-
terminus. Inhibition of FN interaction with the cell surface matrix often results if sulfhydryl 
groups are alkylated. There are possibilities that these sulfhydryls partake in inter-molecular 
disulphide bonding of FN to other FN molecules or to other cell surface components such as 
proteoglycans [67]. 
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2.7.4.6 Heparin-Binding Domain 
FN contains two major heparin-binding domains that have a binding affinity for heparin 
sulphate proteoglycans. Heparin II, the stronger heparin-binding domain is located at the C-
terminus whereas the weaker binding domain, Heparin I, is positioned at the amino-terminal 
end of the protein. Heparin II has a high binding affinity for glycosaminoglycan and 
chondroitin sulphate, whereas Heparin I domain contains a Staphylococcus-aureus-binding 
site that mediates FN interactions with the bacterium. Heparin-binding domains of other cell 
types can induce cell adhesion [69]. 
2.7.5 Fibronectin Depletion: The Association with Tumorigenicity 
Oncogenic transformation leads to pleiotropic changes in cellular properties. Such changes 
include decreased adhesion, rounded morphology and loss of cytoskeletal organization [67]. 
Studies have indicated that loss of FN is also concomitant with this oncogenic transformation 
[67, 71]. In some instances, an addition of FN can be used to revert such changes, thus it is 
possible that they reflect a common effect of the transforming agent. Reduced synthesis, 
reduced binding and increased rates of degradation are some of the factors that have been 
linked to loss of FN. Moreover, in vivo studies have indicated a relation between FN 
depletion and tumorigenesis [67]. These reports suggest that a correlation between FN 
depletion and acquisition of metastatic potential may exist. Given that FN is involved in the 
adhesion of cells to ECMs, tumor invasion and metastasis may induce a shift in the cellular 
function of FN [67]. 
2.8 LANGERHANS CELLS 
In 1868 from a study of the human skin, dendritic leukocytes of the epidermis were first 
identified by a German clinician, Paul Langerhans [13, 72-74]. The study demonstrated that 
cells, which now bear his name, Langerhans, are non-pigmented cells with a dendritic 
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morphology [73, 74]. As time passed, it became apparent that Langerhans cells (LCs) do not 
only reside in the epidermis, but are also present in many other tissues, including the female 
genital tract. In electron microscopy, Birbeck granules contained within LCs serve as the key 
identifying feature of the cells [13, 73-75]. Initially, physiological knowledge of LCs was 
limited. However, culture systems that permit in vitro generation of mouse and human LCs 
are now enabling researchers to gain more insight on the physiology of LCs. In vitro 
production of Human LCs is currently obtained using either bone marrow progenitors 
cultured in granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis 
factor (TNF) or blood monocytes cultured with GM-CSF [72, 76, 77]. 
2.8.1 Langerhans Cells: Regulators of Immune Responses 
LCs are the principal cells that regulate immune surveillance [13, 77-79] of various mucosal 
barriers, including that of the reproductive tract [13]. In the female reproductive tract, LCs 
are hormonally controlled and their role is tightly regulated. LCs play an integral role in 
antigen acquisition and immune effector mechanisms. Moreover, the cells are involved in 
detection and response of the reproductive tract to invading pathogens such as causative 
agents of sexually transmitted infections [13]. Pathogen detection is made possible by the 
presence of Toll-like receptors and C-type lectins on LCs. Such receptors and lectins identify 
pathogen-associated molecular patterns such as constituents of the bacterial wall, or bacterial 
and viral nucleic acid motifs [77]. Conversely, LCs may also present a negative effect on the 
immune system. In one study, a reconstructed vaginal mucosa integrating Langerhans cells 
was developed to provide evidence that Langerhans cells support transmission of HIV-1 
strains to peripheral blood mononuclear cells [80]. 
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2.9 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 
A closed circulatory system consists of a network of blood vessels essential for the 
development and maintenance of all tissues in the body [81]. Normal vasculature is 
architecturally structured to bring oxygen and nutrients to cells, allow for specific exchange 
of contents, and remove waste such as a urea and lactic acid in a streamlined, efficient 
manner [7, 81-83]. Vasculogenesis, the emergence of these blood vessels, is one of the 
earliest events in embryogenesis during which mesodermal cells differentiate into 
hemangioblasts [83, 84]. Vasculogenesis is completed with the formation of the primary 
vascular plexus, and all further transformations and maturation of the vascular network 
proceed during angiogenesis [83].  
2.9.1 Angiogenesis: Modulator for Physiological and Pathological Processes 
Angiogenesis, a complex process of new blood vessel formation from pre-existing vascular 
networks [81, 83, 85-88], is critical for the development and maintenance of any living tissue 
[7]. Angiogenesis is closely regulated by a balance between factors that stimulate and factors 
that inhibit the development of new vasculature [87, 89]. Angiogenesis is essential for both 
physiological and pathological processes [87, 90]. In healthy adults, the levels of angiogenic 
factors are in equilibrium and ECs are mostly quiescent [85, 87]. Under such circumstances, 
angiogenesis is restricted to certain processes such as wound healing, development and 
reproduction. Nonetheless, under pathologic states such as tumor growth, progression and 
metastasis [81, 82, 87, 89], rheumatoid arthritis, and atherosclerosis [81, 87], pathologic 
angiogenesis comes into play [81, 82, 87]. During pathologic angiogenesis, the balance of 
pro- and anti-angiogenic factors is shifted such that the production of pro-angiogenic factors 
outweighs anti-angiogenic factors, resulting in new blood vessel formation [85, 87, 89]. 
Increased blood vessel formation provides tumors with oxygen and nutrients which enable 
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the growth and progression of tumors [81, 87]. Angiogenic factors responsible for this shift 
include hypoxia, activated oncogenes and metabolic stress [86].  
During the past two decades, extensive studies have indicated that several factors including 
vascular endothelial growth factor (VEGF), angiopoietin and ephrins are major contributors 
of blood vessel formation [91]. Among these pro-angiogenic factors, the VEGF family 
proteins and receptors have been the center of interest. They have thus, been extensively 
characterized due to their prominent role as angiogenesis mediators [7, 81, 85]. This section 
proceeds by describing VEGF-VEGFRs and their role in angiogenesis and vasculogenesis 
2.9.2 VEGF Family and Receptors 
Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein with a molecular 
weight of 34-45 kDa [85, 86]. VEGF, also known as vascular permeability factor (VPF) [7], 
undergoes alternative splicing to yield mature proteins of 121, 165, 189 and 206 amino acids 
[85]. The VEGF family consists of 7 secreted glycoproteins: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F and placental growth factor (PIGF) [81, 85, 86]. All members 
except VEGF-E and svVEGF are encoded in the mammalian genome [81]. Three high-
affinity VEGF tyrosine kinase receptors that have been identified include VEGF receptor 
(VEGFR)-1 (flt-1), VEGFR-2 (flk-1/KDR) and VEGFR-3 (flt-4) [81, 83, 86, 91]. These 
receptors belong to the superfamily of receptor tyrosine kinases (RTKs) [83]. Based on 
structural features, these receptors are highly homologous to each other [83, 85, 87, 91]. 
VEGFR-1 and VEGFR-2 consist of 1338 and 1356 amino acids in humans, respectively [91]. 
Furthermore,VEGFR-1 and VEGFR-2 consist of 7 extracellular immunoglobulin-like 
domains (Ig 1-VII) [81, 83, 85, 91], a single transmembrane protein, and a consensus tyrosine 
kinase (TK) domain, which is interrupted by an inter-kinase insert to yield TK-1 and TK-2 
fragments  [83, 85, 87]. VEGFRs have an additional downstream carboxy terminal region 
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[87, 91]. The different VEGF family members have distinct binding affinities for their 
respective receptors [84, 85]. All VEGF-A isoforms bind to VEGFR-1 and VEGFR-2, 
whereas PIGF1, PIGF2 and VEGF-B have a binding affinity for only VEGFR-1. VEGF-C 
and VEGF-D bind to VEGFR-2 and VEGFR-3, whereas VEGF-E has a specific binding 
affinity for VEGFR-2 [85]. 
2.9.3 Expression and Differential Roles of VEGFs and VEGFRs 
2.9.3.1 VEGF-A: A Key Mediator for Angiogenesis 
In vivo experiments have demonstrated that VEGFs play a crucial role in physiologic 
vasculogenesis and angiogenesis [85]. Moreover, VEGFs are also involved in inflammatory 
processes [83]and other pathologic conditions such as arthritis, diabetic retinopathy and 
psoriasis [83, 85]. VEGF expression is triggered by hypoxia. This has been demonstrated by 
a highly expressed VEGF mRNA under conditions of low oxygen in pathological cases. 
Furthermore, VEGF expression is enhanced by a wide range of factors that include epidermal 
growth factor (EGF), transforming growth factors (TGFα and TGFβ), insulin-like growth 
factor 1 (IGF-1), fibroblast growth factors (FGR) and platelet derived growth factors (PDGF) 
[83].  
VEGF-A is a major regulator for angiogenesis that interacts and stimulates two tyrosine 
kinase receptors VEGFR-1 and VEGFR-2 [84]. It has been reported that VEGF-A is over-
expressed in many human solid tumors [83, 85], which ultimately induces new blood vessel 
formation in the growing tumor [83]. Tumor vessels are readily permeable, and this allows 
tumor cells to penetrate their surrounding vascular networks and metastasize to other organs 
[83]. This is associated with tumor progression and poor prognosis [85]. 
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2.9.3.2 The Initial Expression of the VEGF Receptors 
During murine development, the expressions of both VEGFR-1 and VEGFR-2 are initially 
detected at E7.5 in mesodermal cells of the tail region [91]. At E7.5-8.0, VEGFR-2 positive 
cells migrate to the head region and yolk sac, and differentiate into primitive ECs [91]. 
Hematopoiesis is initiated when ECs create blood islands at yolk sac [91]. Interestingly, 
VEGFR-1 and VEGFR-2 have also been detected in both liquid and solid tumor cells [84]. 
Gene targeting studies in mice have indicated that VEGFs and VEGFRs play a role in 
development of a vascular system [84]. In these studies, VEGF appears particularly important 
because loss of even a single Vegf allele results in embryonic lethality at days 11 to 12 [84]. 
Vegfr2-/- mice die at embryonic days 8.5 to 9.5 due to defect in the development of 
hematopoietic and ECs resulting from impaired vasculogenesis [84]. Moreover, members of 
the VEGF family are involved in other biological processes, including lymphangiogenesis, 
vascular permeability, and hematopoiesis [84]. 
2.9.3.4 VEGFR-1: A Negative Regulator for Angiogenesis and a Positive Regulator of 
Macrophage Functions 
Initially, VEGFRs were reported to be expressed exclusively on various ECs [85]. However, 
emerging evidence indicates that VEGFRs are also expressed by other cell types including 
tumor cells [85]. In addition to ECs, VEGFR-1 is also expressed by macrophages, 
monocytes, hematopoietic stem cells and certain non-endothelial cells [81, 84]. VEGFR-1 
and VEGFR-2 play a role in physiological and pathological angiogenesis [84]. In early 
embryogenesis, the soluble form of VEGFR-1 acts as a negative regulator of VEGF-A by 
inhibiting VEGF-A and VEGFR-2 interaction [84]. This antagonistic action is essential to 
maintain equilibrium for an appropriate level of angiogenesis [84, 91]. The role of VEGFR-1 
as a negative regulator of VEGF-A has been established from data of gene activation 
experiments in which Flt1-/- mice died between 8.5 and 9.5 days of embryonic development 
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due to excessive growth and disorganization of blood vessels [84]. VEGFR-1 induces tumor 
growth, metastasis, and inflammation in partly a macrophage-dependent manner [91]. This 
receptor interacts with its ligands to initiate dimerization followed by 
trans/autophosphorylation of tyrosine residues at the cytoplasmic kinase domain. However, 
autophsphorylation of VEGFR-1 by VEGF-A is weak [83]. It has been suggested that 
VEGFR-1 is mainly a negative regulator of the activity of VEGF-A on vascular endothelial 
cells rather than mitotic signal transduction. This suggestion was based on structural 
peculiarity of VEGFR-1 as its soluble form produced by alternative splicing [83]. This form 
is not a transmembrane protein and has no tyrosine kinase domain, thus its inability to 
transduce a signal.VEGFR-1 also plays a role in blood vessel permeability [83]. VEGFR-1 
mediates monocyte migration, recruitment of EC progenitors, hematopoietic stem cell 
survival and release of growth factors from liver ECs [84]. 
2.9.3.5 VEGFR-2: A Key Receptor for Angiogenesis  
From the postnatal to adult stages, VEGFR-2 is readily expressed in ECs [84, 91]. In 
endothelial cells, VEGF-A stimulates VEGFR-2 gene expression via a positive feedback 
mechanism [91]. In addition to that, this receptor is expressed in a fraction of hematopoietic 
cells which may be the progenitor for ECs [84, 91]. However, the level of expression is 
significantly lower than that found in ECs, thus, it is inconclusive whether low VEGFR-2 
levels in hematopoietic cells could have any biological impact [91]. A low VEGFR-2 
expression is also observed in neuronal cells, osteoblasts, pancreatic duct cells, and 
progenitor cells. Biological role of VEGFR-2 in these non-endothelial cells remains unclear 
[91]. In tumor vasculature, VEGFR-2 expression is 3-5-fold higher than in normal 
vasculature [91]. 
VEGFR-2 has now been accepted as the main mediator of VEGF-A biological activity [83]. 
VEGFR-2 is actively involved in both embryonic angiogenesis and hematopoiesis [83]. Mice 
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with an inactive gene flk1 die between 8.5 and 9.5 days of embryonic development [83]. The 
death of the animals results from disturbed vasculogenesis, as well as lack of EC 
differentiation and hematopoiesis [83]. Activation of VEGFR-2 stimulates a number of signal 
transduction pathways that induce mitogenesis, migration and survival of ECs [83]. This has 
been confirmed from in vivo studies in which inactivation of VEGFR-2 inhibited 
angiogenesis whereas activation of the receptor had an opposite effect [83]. In addition to 
that, VEGF-E, which interacts exclusively with VEGFR-2 induced cell proliferation and 
formation of tubular structures in endothelial cells in vitro and stimulated in vivo 
angiogenesis [83].  
2.9.3.6 VEGFR-3: The Lymphangiogenesis Key Receptor  
The expression of VEGFR-3 occurs during late stages of embryonic development. This 
receptor is mainly restricted to the lymphatic system endothelium [83, 84]. It regulates 
lymphangiogenesis [83, 84], a process that becomes selectively affected when the 
intracellular signaling pathways associated with this receptor are disturbed [83]. 
2.10 IMMUNOHISTOCHEMISTRY: A POWERFUL DIAGNOSTIC TOOL 
The introduction of immunochemical techniques in routine pathology laboratories has 
enabled pathologists to improve their diagnostic abilities. Immunohistochemistry (IHC) is a 
crucial and powerful diagnostic tool that serves to identify and localize distinct antigens in 
tissues or cells based on antigen-antibody recognition [92-94]. Immunohistochemistry also 
termed immunocytochemistry seeks to exploit the specificity that occurs during the 
interaction of an antibody with its antigen-antigen at a light microscopic level [92]. This 
technique does not only enable detection of abnormal tissues, but it also enables pathologists 
to determine the immunophenotype of normal cells and neoplastic counterparts [93]. 
Immunohistochemistry is a critical tool in illustrating tumor cell lineage and metastasis. 
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Moreover, immunohistochemical semi-quantitative data is often used in the identification and 
illustration of prognostic and predictive markers [92]. This means that immunohistochemical 
staining may have therapeutic implications in various diseases.  
2.10.1 Immunohistochemical Stain: More than just a special Stain  
As emphasized by pioneers in the field of functional morphology, the primary objective of all 
staining techniques is to identify micro-chemically the existence and distribution of 
components that have already been identified macro-chemically. The basic critical principle 
of special stains, including immunohistochemical stains, is a sharp visual localization of 
target components in cells or tissues, based on satisfactory signal-to-noise ratio [92]. Over the 
years, several technical developments have led to the extensive use of immunohistochemistry 
today. In surgical pathology laboratories, antigens can now be successfully demonstrated in 
routinely processed formalin-fixed paraffin-embedded (FFPE) tissues [92, 95]. The 
enzymatic label (horseradish peroxidase) with a suitable chromogenic substrate allows 
visualization of the labelled antibody by light microscopy. A rapid growth of commercially 
available antibodies and the on-going refinement of immunohistochemical tools contribute 
towards the pivotal role of immunohistochemistry in medical diagnostic procedures. 
Moreover, demands for improved reproducibility and quantification have made researchers 
aware that immunohistochemistry can be ‘more than just a special stain’. If all 
immunohistochemical processes are sufficiently monitored, the technique can provide tissue-
based immune-assay with reproducibility and quantitative features similar to those of an 
enzyme-linked immunosorbent assay (ELISA) test. This means that not only will the protein 
or antigen be detected, but an accurate and reliable amount of that particular antigen will be 
measurable [92]. 
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2.10.2 IHC Detection Systems 
Various IHC methods have been established to achieve greater sensitivity during the staining 
of FFPE tissues. The methods range from a one-step direct conjugate detection system to 
multiple-step detection systems such as peroxidase anti-peroxidase (PAP), avidin-
biotinconjugates (ABC) and biotin-streptavidin (B-SA). The main methods of 
immunostaining that are readily used include direct, indirect, alkaline phosphatase, 
peroxidase-anti-peroxidase and avidin-biotin methods [93]. In the study, the indirect 
conjugate (sandwich) method was used. It is a relatively simple modification of the direct 
conjugate method [92]. 
2.11 CONCLUDING REMARKS 
Chapter 2 outlined the biology of human vaginal mucosa and the value of athymic nude mice. 
The chapter was continued by exploring human and murine markers under investigation. The 
chapter was concluded by a brief discussion of immunohistochemistry. Chapter 3 will give a 
detailed description of the research methodology, including a procedure for 
immunohistochemistry. 
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CHAPTER THREE 
MATERIALS AND METHODS 
3.1 ETHICAL APPROVAL 
This study is a follow-up of two previous MSc research studies conducted separately by 
Wang [5] and Kok [6] for which prior ethical approval had been granted by the University of 
Stellenbosch and the University of the Western Cape (Reference Numbers N09/10/271 and 
N05/04/061).  This study is partly a validation and partly a further investigation of the tissue 
characteristics of a novel in-vivo research model. It verifies the results and introduces 
enlightening statistics on the interpretation of the staining intensities of tissue preparations 
reported previously by Kok [6]. 
3.2 EXPERIMENTAL DESIGN – PART 1: TISSUE PREPARATION 
3.2.1 Cyst Production 
Human vaginal mucosa was obtained from Tygerberg Hospital (Cape Town, South Africa) in 
a study conducted by Wang and Hille [5]. The vaginal mucosa had been removed during 
corrective procedures. A carrier medium containing 10% foetal calf serum (Delta 
Bioproducts, SA); minimum essential medium; streptomycin, penicillin and amphotericin-β 
was used to transport vaginal mucosa to the laboratory. In the laboratory, vaginal mucosa was 
divided twice, one portion served as a control for immunohistochemical examination whereas 
the other portion was used to produce experimental cysts. From the latter portion, the 
epithelium and its underlying connective tissue were separated with extreme caution in order 
to avoid injury to vaginal epithelium. Moreover, this was done to enhance successful 
separation of the epithelium from the connective tissue. Epithelial fragments of 
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approximately 8 X 4 mm in size were prepared. A glass ball of 2 mm in diameter was placed 
on each epithelial fragment and the tissue was sutured around the glass ball with DexonR 
(DG American Cyanamid Company, USA). A total of 24 cysts were prepared. Stringent 
infection control measures were also applied to reduce potential bacterial infection of vaginal 
epithelium. 
3.2.2 Athymic Nude Mice 
Male athymic mice aged 4-6 weeks were obtained from the Animal House at the University 
of Cape Town (Cape Town, South Africa). The animals were housed in pathogen-free 
isolators under controlled conditions of light and humidity. The temperature was maintained 
at 26°C and a light cycle consisting of 12 hours of light and 12 hours of darkness. The mice 
were provided with a suspension of 1.8% tetracycline in their drinking water. Sterilized mice 
feed was also provided ad libitum. 
3.2.3 Cyst Xenografts 
The cysts were xenografted into the dorsal neck region of immune-deficient mice using a 
trocar. Only one cyst was implanted per animal. Successful integration of newly implanted 
experimental cysts in host nude mice was achieved 9-weeks post implantation. During the 9-
week period, terramycin and/or gentamicin were administered to the animals to minimize the 
high risk of infection associated with xenografts. 
3.2.4 Cyst Retrieval 
After a 9-week period, the implanted cysts were harvested from the animals. The animals 
were anaesthetized with a mixture of fentanyl and hypnodil. Surgical procedures were 
performed under sterile conditions. The cysts were fixed in buffered formalin, routinely 
processed and embedded in paraffin wax for subsequent use. Cysts with a morphologically 
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intact vaginal epithelium, a conspicuous adjacent stroma and no illustrations of infection 
were used. Cysts that were ruptured with excessive inflammation and signs of infection were 
excluded. As a result of the above mentioned selection criteria, only 10 cysts were in 
conditions suitable for experimental purposes. In this study, the phrases ‘normal vaginal 
tissues’ and ‘xenografted vaginal tissues’ refers to original tissues and their paired implanted 
cysts, respectively. 
3.3 EXPERIMENTAL DESIGN – PART 2: IMMUNOHISTOCHEMISTRY 
3.3.1 Principle 
As already stated in Chapter 2, immunohistochemistry is a technique used for localizing 
specific antigens in tissues or cells based on antigen-antibody recognition [92]. This method 
exploits the specificity provided by antibody-antigen interaction at a light microscopic level. 
The basic critical principle of immunohistochemistry is a sharp visual localization of target 
components in a cell and tissue, based on satisfactory signal-to-noise ratio [92]. In daily 
practice, satisfactory results are obtained by amplifying the signal while simultaneously 
reducing specific background staining. In this study, indirect conjugate (sandwich) detection 
system was used to localize human and murine markers in normal vaginal tissues and 
xenografted vaginal tissues. In this method, the primary antibody that has specificity against 
the antigen in question (e.g., rabbit anti-mouse antibody) was added to a vaginal tissue 
section, and excess antibody was rinsed off. The labeled secondary antibody, which has 
specificity against the antigen on the primary rabbit antibody, was then added. Adding a 
secondary antibody is important for labeling sites on the tissue that express the primary 
antibody, which, in turn, is bound to the antigen [92]. 
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Figure 3.1: Indirect Conjugate (Sandwich) Method. The primary antibody is unlabeled. The method uses a 
labeled secondary antibody, having specificity against the primary antibody. Boxed-Antigen determinant on 
primary antibody; Px-Peroxidase label; F-Fluorescein label. Source: [92]. 
3.3.2 Antibodies 
Mouse anti-human primary antibodies raised against 10 human antigens were used. Human 
primary antibodies used were; anti-cytokeratin 1, anti-cytokeratin 5, anti-cytokeratin 13, anti-
cytokeratin 14, anti-collagen type IV, anti-laminin, anti-elastin, CD1a, anti-fibronectin and 
anti-VEGFR-3 (Leica Microsystems, SA). Rabbit anti-mouse primary antibodies raised 
against 6 mouse antigens were also used. The primary antibodies directed against mouse 
antigens included anti-collagen type IV, anti-laminin, Langerin, anti-fibronectin and anti-
VEGFR-2 (Biocom Biotech CC, SA). 
Table 3.1: Rabbit Anti-Mouse Antibodies used for Immunohistochemical Analysis of Murine Markers 
Antibody Reference 
Code 
Specificity Dilution Antigen Retrieval Method 
C7510-50S Collagen type IV 1:100 EDTA/Citrate Buffer Solution 
LS-C25107 Laminin 1:100 EDTA/Citrate Buffer Solution 
F4215-46 Fibronectin 1:100 EDTA/Citrate Buffer Solution 
LS-C735 Langerhans cells 1:100 EDTA/Citrate Buffer Solution 
V2100-17C2 VEGFR-2 1:50 EDTA/Citrate Buffer Solution 
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Table 3.2: Mouse Anti-Human Antibodies used for Immunohistochemical Analysis of Human Markers 
Antibody Reference 
Code 
Specificity Dilution Antigen Retrieval Method 
NCL-CK1 Cytokeratin 1 1:20 EDTA Buffer Solution 
NCL-CK5 Cytokeratin 5 1:100 EDTA/Citrate Buffer Solution 
NCL-CK13 Cytokeratin 13 1:100 EDTA Buffer Solution 
NCL-LL002 CK14 Cytokeratin 14 1:20 EDTA Buffer Solution 
NCL-COLL-IV Collagen type IV 1:100 Enzyme Digestion 
NCL-LAMININ Laminin 1:100 Enzyme Digestion 
NCL-ELASTIN Elastin 1:100 Enzyme Digestion 
NCL-FIB Fibronectin 1:100 Enzyme Digestion 
NCL-CD1A-235 Langerhans cells 1:15 EDTA/Citrate Buffer Solution 
NCL-L-VEGFR-3 VEGFR-3 1:50 EDTA/Citrate Buffer Solution 
 
3.3.3 Procedure 
Formalin-fixed, paraffin embedded blocks were cut into 3 µm sections. The sections were 
mounted on positively charged slides coated with Poly-L-Lysine solution (Sigma Aldrich, Pty 
Ltd, SA) and incubated overnight at 26°C. The first step involved dewaxing (deparaffinizing) 
tissue sections in xylene for 5 minutes, followed by immersing them in decreasing grades of 
alcohol for 2 minutes with each alcohol. 2X 100% alcohol, 2X 96% alcohol and 1X 70% 
alcohol were used. Sections were washed in water (H2O) for 4 minutes and distilled water 
(dH2O) for 2 minutes. Human antigen retrieval using anti-cytokeratin 1, anti-cytokeratin 13 
and anti-cytokeratin 14 antibodies was performed using ethylene diamine tetracetic acid 
(EDTA) based buffer of pH 9.0 at 100°C for 10-15 minutes. Human antigen retrieval using 
anti-cytokeratin 5; CD1a and anti-VEGFR-3 antibodies was performed using citrate buffer of 
pH 6.0 at 100°C for 10-15 minutes. Human antigen retrieval using anti-collagen type IV; 
anti-laminin, anti-elastin and anti-fibronectin antibodies was performed using pepsin 
digestion method at 37°C for 30 minutes. All mouse antigens were retrieved using EDTA 
based buffer of pH 9.0 at 100°C for 10-15 minutes. A summarized version of the methods 
used for antigen retrieval is indicated on Table 3.1 and Table 3.2. Sections were washed in 
phosphate buffer solution (PBS), immersed in 3% hydrogen peroxide (H2O2) to block 
endogenous peroxidase activity, and washed again in PBS. Subsequent blocking was done 
with normal rabbit serum of 1:20 dilution for 20 minutes. Excess PBS was drained off and 
 
 
 
 
38 
tissue slides were dry-blotted to prevent further dilution of antibodies in PBS during 
incubation. Excess PBS was also removed to enhance optimum binding of antibodies. 
Sections were incubated with 250 µl primary antibodies at room temperature for 30 minutes 
and rinsed in PBS for 2 minutes. Sections were then incubated with 300 µl biotinylated 
secondary link antibodies at room temperature for 30 minutes and rinsed in PBS. Further 
incubation of sections was done with 300 µl streptavidin horse radish peroxidase (HRP) at 
room temperature for 30 minutes. A chromogen substrate consisting of 1 ml substrate buffer 
and 50 µl 3,3-diaminobenzidine (DAB) was added to each section. Sections were incubated 
at room temperature for 10 minutes, rinsed in water for 2 minutes and immersed in 
hematoxylin for 25 seconds. Sections were dehydrated using an increasing grade of alcohols 
by dipping sections 10 times per alcohol. Increasing grades of alcohol used were 1X 70% 
alcohol, 2X 96% alcohol and 2X 100% alcohol. Slides were rinsed with 2X xylene to ensure 
complete dehydration. A small drop of DPX mountant (glue) (Sigma Aldrich, Pty Ltd, SA) 
was placed on each cover slip and stained sections were subsequently mounted onto cover 
slips. Sections were left to air dry before being analyzed. 
3.3.4 Light Microscopy 
Tissue sections were analyzed by brightfield using 10X, 20X and 40X objectives of Nikon 
Eclipse 55! microscope (Nikon Instruments, Inc.). Images were taken using NIS Elements 
(Nikon Instruments, Inc.) software and Nikon Digital Sight DS-U2 camera (Nikon 
Corporation). Immunohistochemical structures of interest such as the epithelium, basement 
membrane and stromal layer were assessed on each tissue section. Sections were scored 
according to a scale explained in the next section. 
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3.3.5 Scoring Criteria 
Following immunohistochemical staining of normal tissues and xenografted tissues, staining 
intensity of markers was assessed along the epithelium, the basement membrane and stromal 
layer. Staining intensity for each tissue was scored according to a semi-quantitative scoring 
system stipulated on Table 3.3 and Table 3.4. Semi-quantitative scoring procedure was 
performed in triplicate. Tissue sections were awarded a score of between 0 and 4 for all 
human and murine markers except for collagen IV and laminin which could only be awarded 
a maximum score of 3. 
Table 3.3: Immunohistochemical Scoring Criteria for Human and Murine Markers 
IHC Score Description of the IHC Score 
0 Negative Staining (No Positively Stained Cells) 
1 Very Few Positively Stained Cells (10-25%) 
2 Rare Positive Staining (25-50%) 
3 Strong, Non-Uniform Positive Staining (50-75%) 
4 Strong, Uniform Positive Staining (>75%) 
 
Table 3.4: Immunohistochemical Scoring Criteria for Collagen IV and Laminin 
IHC Score Description of the IHC Score 
0 Negatively Stained Basement Membrane 
1 Rare Positively Stained Basement Membrane 
2 Strong, Interrupted Stained Basement Membrane 
3 Strong, Uniformly Stained Basement Membrane 
4  
 
In selected cases, immunohistochemical scores staining scores were recorded by two 
independent observers before final scores could be established. This was done to ensure that 
optimum scores were used for statistical analysis. 
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3.4 STATISTICAL ANALYSIS 
Staining intensities were statistically analyzed using GraphPad Prism5.0 (GraphPad 
Software, Inc). Firstly, Normality tests were performed to determine whether or not the data 
was sampled from a Gaussian distribution. Since the data was not normally distributed, 
repeated-measures one-way ANOVA with subsequent non-parametric Friedman’s test was 
used to compare mean staining intensity of the paired vaginal tissues. Since Friedman’s test 
ranks values in each row, it is not affected by sources of variability that may equally affect all 
values in a row. This matched test was therefore chosen to control experimental variability 
between tissue sections, and thus enhancing the power of the test statistic. Dunn’s post-test 
was chosen to make further multiple comparisons between normal and xenografted vaginal 
tissues. Scores reported from Kok’s study were also statistically assessed. A significance 
level of P<0.05 was used for all tests and comparisons. All comparisons were conducted in 
triplicate to avoid statistical errors. Results were expressed in terms of mean ± standard error 
of mean (SEM). 
3.5 POSITIVE CONTROLS 
In order to ascertain immunohistochemical staining results, positive controls that were processed 
in-house by Kok [6] were used in the current study. 
3.5.1 Positive Human Tissue Controls 
Seven human surgical tissues were used as positive controls (Table 3.5). The tissues had been 
obtained from the Division of Anatomical Pathology of the national health laboratory service 
(NHLS) (Tygerberg Hospital, Cape Town, South Africa). 
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Table 3.5: Positive Human Control Tissues Used for Validation of IHC Staining 
Mouse Anti-Human Antibody Antibody Reference Code Positive Control Tissue 
Cytokeratin 1 NCL-CK1 Human Skin 
Cytokeratin 5 NCL-CK5 Human Prostate 
Cytokeratin 13 NCL-CK13 Human Tonsil 
Cytokeratin 14 NCL-LL002 CK14 Human Skin 
Collagen Type IV NCL-COLL-IV Kidney/Basement Membrane 
Laminin NCL-LAMININ Kidney/Small Intestine 
Elastin NCL-ELASTIN Kidney/Small Intestine 
Fibronectin NCL-FIB Normal Kidney 
CD1a (Langerhans Cells) NCL-CD1A-235 Human Skin 
VEGFR-3 NCL-L-VEGFR-3 Human Placenta 
 
3.5.2 Positive Mouse Tissue Controls 
Two athymic nude mice obtained from the Animal House at the University of Cape Town 
(Cape Town, South Africa) had been used to process mouse tissues that served as positive 
controls. The mice had been dissected by Kok [6] at the division of Anatomical Pathology of 
the NHLS (Tygerberg Hospital, Cape Town, South Africa). 
Subsequent tissue fixation had been performed at the division of Anatomy and Histology of 
the NHLS (Tygerberg Hospital, Cape Town, South Africa). Table 3.6 lists mice tissues that 
served as positive controls for IHC staining. 
Table 3.6: Positive Mouse Control Tissues Used for Validation of IHC Staining 
Rabbit Anti-Mouse Antibody Antibody Reference  Positive Control Tissue 
Collagen Type IV C7510-50S Mouse Kidney / Liver 
Laminin LS-C25107 Mouse Skin / Liver 
Fibronectin F4215-46 Mouse Skin / Liver 
Langerhans Cells LS-C735 Mouse Lung / Skin 
VEGFR-2 V2110-17C2 Mouse Pancreas / Kidney 
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3.6 NEGATIVE CONTROLS 
Negative tissue controls were included in the study to confirm the specificity of the 
immunohistochemical test and to assess the presence of non-specific background staining. 
Negative controls used had also been prepared in a previous study by Kok [6]. Normal human 
vaginal mucosa was used as a negative control. This step was important to substantiate the 
specificity of mouse antigen markers as well as to exclude cross reactivity with human 
antigens. 
3.6.1 Negative Tissue: Control 1 
The 1st negative control was a tissue section in which rabbit anti-mouse antibody was 
replaced with PBS. This was done to identify any false positive results. 
3.6.2 Negative Tissue: Control 2 
The 2nd negative control was incubated with a primary antibody and biotinylated secondary 
antibody and streptavidin HRP were replaced with PBS. The second control was included to 
verify negative staining of antigens. 
3.7 ACCRONYMS USED IN THE STUDY 
The acronyms NVT and XVT shall be used to denote normal vaginal tissues and xenografted 
vaginal tissues, respectively. NVTα and XVTα will denote normal and xenografted vaginal 
tissues of the previous study, respectively. The letters –h and –m will denote localization of 
human and mouse antigens (markers) respectively. 
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CHAPTER FOUR 
RESULTS  
4.1 HUMAN CYTOKERATIN 1 EXPRESSION PROFILE 
4.1.1 Immunohistochemical Scores for Cytokeratin 1 
Varied staining patterns of Cytokeratin 1 (CK1) were observed along the epithelium in both 
normal and xenografted vaginal tissues. All normal tissues displayed a moderate to strong 
positive staining of CK1. Weak reactivity patterns were seen in 6 of 10 xenografted tissues 
whereas the remaining 4 of 10 tissues stained negatively for CK1 (Table 4.1). 
Table 4.1: Immunohistochemical Scoring of Human Vaginal Mucosa for Cytokeratin 1. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. Mouse anti-
human monoclonal antibody raised against cytokeratin 1 antigens was used in both tissues. 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue 
NCL-CK1 Ab 
Xenografted Vaginal Tissue 
NCL-CK1 Ab 
15392/06 2 0 
15396/06 4 0 
16173/06 2 1 
16175/06 4 1 
16176/06 4 2 
8960/06 3 0 
8961/06 3 2 
10156/06 4 1 
17559/06 4 1 
17560/06 4 0 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-CK1 - Reference Code for Human Cytokeratin 1 Antibody; Ab - Antibody. 
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4.1.2 Statistical Comparisons of Cytokeratin 1 Staining Intensities 
Mean staining intensities for cytokeratin 1 in NVT, XVT, NVTα and XVTα were 3.4±0.2667, 
0.8±0.2494, 3.8±0.2000 and 1.3±0.3350, respectively. Repeated-measures one-way ANOVA 
with subsequent Friedman’s test (Friedman Statistic=27.69) showed significant differences in 
the staining intensities between the tissue groups (P<0.0001). Dunn’s post-test for multiple 
comparisons of the groups showed significant differences between NVT and XVT, NVTα and 
XVTα (P<0.05). A high significant difference was noted between NVTα and XVT (P<0.05). 
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Figure 4.1: Mean Cytokeratin 1 Staining Intensity by Vaginal Mucosal Type. Data is expressed 
as mean ± standard error of mean (n=10). Friedman’s test indicates that tissue types are significantly 
different (P<0.0001). Dunn’s post test specifies tissue types that are significantly different (P<0.05) 
as denoted by similar alphabets.  
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work. 
*Significant; **Very Significant; ***Extremely Significant 
a**
a**
b***
 b***
 c**
c**
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4.1.3 Photomicrographs of Vaginal Mucosae Stained for Cytokeratin 1 
  
  
 
Figure 4.2. Immunohistochemical Staining of Cytokeratin 1 on Vaginal Mucosal Tissues. CK1 staining 
performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal tissues. Small arrows 
point to cells expressing CK1. Big arrow points to superficial and intermediate epithelial layers where CK1 
is predominantly expressed. Ep-Epithelium; BM-Basement Membrane; CT-Connective Tissue. 
(Magnifications X100). 
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4.2 HUMAN CYTOKERATIN 5 EXPRESSION PROFILE 
4.2.1 Immunohistochemical Scores for Cytokeratin 5 
Cytokeratin 5 (CK5) was abundantly present in both normal and xenografted tissues. Positive 
staining was expressed along the epithelium, particularly on the basal layer (Figure 4.4). A 
strong, widespread distribution pattern was reported in 8 of 10 normal tissues and in 3 of 10 
xenografted tissues (Table 4.2). Positive staining with rare interruptions was observed in 7 of 
10 xenografted tissues. 
Table 4.2: Immunohistochemical Scoring of Human Vaginal Mucosa for Cytokeratin 5. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. Mouse anti-
human monoclonal antibody raised against cytokeratin 5 antigens was used in both tissues. 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue 
NCL-CK5 Ab 
Xenografted Vaginal Tissue 
NCL-CK5 Ab 
15392/06 4 3 
15396/06 4 3 
16173/06 4 3 
16175/06 4 4 
16176/06 4 4 
8960/06 3 3 
8961/06 3 3 
10156/06 4 4 
17559/06 4 3 
17560/06 4 2 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-CK5 - Reference Code for Human Cytokeratin 5 Antibody; Ab - Antibody. 
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4.2.2 Statistical Comparisons of Cytokeratin 5 Staining Intensities 
Mean staining intensities for cytokeratin 5 in NVT, XVT, NVTα and XVTα were 3.8±0.1333, 
3.2±0.2000, 4.0±0.0000 and 3.6±0.1633, respectively. Repeated-measures one-way ANOVA 
with subsequent Friedman’s test (Friedman Statistic=13.35) indicated significant differences 
in the mean staining intensities between the tissues (P=0.0039). However, according to 
Dunn’s multiple comparison test, there were no statistically significant differences in the 
staining intensities between all the tissue groups (P>0.05)  
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Figure 4.3: Mean Cytokeratin 5 Staining Intensity by Vaginal Mucosal Type. Data is expressed 
as mean ± standard error of mean (n=10). Friedman’s test indicates a significant difference between 
tissue types (P=0.0039). Conversely, Dunn’s post test indicates that tissue types are not significantly 
different (P>0.05). 
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work. 
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4.2.3 Photomicrographs of Vaginal Mucosae Stained for Cytokeratin 5 
  
  
 
Figure 4.4. Immunohistochemical Staining of Cytokeratin 5 on Vaginal Mucosal Tissues. CK5 staining 
performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal tissues. Small arrows 
point to cells expressing CK5. Big arrow points to the basal epithelial layer where CK5 is mostly localized. 
Ep-Epithelium; BM-Basement Membrane; CT-Connective Tissue. (Magnifications X100 for A, C, D and 
X200 for B). 
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4.3 HUMAN CYTOKERATIN 13 EXPRESSION PROFILE 
4.3.1 Immunohistochemical Scores for Cytokeratin 13 
Normal and xenografted vaginal tissues displayed positive staining for cytokeratin 13 
(CK13). CK13 was observed along the superficial, intermediate and parabasal layers of the 
epithelium (Figure 4.6) in both normal and xenografted tissues. A relatively similar strong 
staining pattern was reported in 9 of 10 normal tissues. A moderate to strong staining of 
CK13 was noted in 9 of 10 xenografted tissues while 1 xenografted tissue stained negatively 
(Table 4.3) 
Table 4.3: Immunohistochemical Scoring of Human Vaginal Mucosa for Cytokeratin 13. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. Mouse anti-
human monoclonal antibody raised against cytokeratin 13 antigens was used in both tissues. 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue 
NCL-CK13 Ab 
Xenografted Vaginal Tissue 
NCL-CK13 Ab 
15392/06 4 4 
15396/06 4 0 
16173/06 4 4 
16175/06 4 3 
16176/06 4 3 
8960/06 4 3 
8961/06 4 3 
10156/06 3 2 
17559/06 4 3 
17560/06 4 2 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-CK13 - Reference Code for Human Cytokeratin 13 Antibody; Ab - Antibody. 
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4.3.2 Statistical Comparisons of Cytokeratin 13 Staining Intensities 
Mean staining intensities for cytokeratin 13 in NVT, XVT, NVTα and XVTα were 
3.9±0.1000, 2.7±0.3667, 4.0±0.0000 and 4.0±0.0000, respectively. Repeated-measures one-
way ANOVA with subsequent Friedman’s test (Friedman Statistic=22.76) indicated 
significant differences in the mean staining intensities between all tissue groups (P<0.0001). 
Further statistical analysis with Dunn’s multiple comparison test showed significant 
differences between NVTα and XVT and between XVT and XVTα (P<0.05). 
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Figure 4.5: Mean Cytokeratin 13 Staining Intensity by Vaginal Mucosal Type. Data is expressed 
as mean ± standard error of mean (n=10).  Friedman’s test indicates a statistical difference between 
tissue types (P<0.0001). Further analysis with Dunn’s post test shows tissue types that are 
significantly different (P<0.05) as denoted by similar alphabets. 
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work. 
*Significant 
 a*
 b*
a*  b*
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4.3.3 Photomicrographs of Vaginal Mucosae Stained for Cytokeratin 13 
  
  
 
Figure 4.6. Immunohistochemical Staining of Cytokeratin 13 on Vaginal Mucosal Tissues. CK13 
staining performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal tissues. Small 
arrow points to a cell expressing CK13. Big arrows point to the parabasal epithelial layer where CK13 is 
mostly localized. A star indicates diffusely expressed CK13 in all epithelial layers of this particular 
xenografted tissue. Ep-Epithelium; CT-Connective Tissue. (Magnifications X100). 
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4.4 HUMAN CYTOKERATIN 14 EXPRESSION PROFILE 
4.4.1 Immunohistochemical Scores for Cytokeratin 14 
Cytokeratin 14 (CK14) was demonstrated consistently in both normal and xenografted 
vaginal tissues. CK14 was predominantly localized to the basal epithelial layer (Figure 4.8). 
A strong, uniformly stained epithelium was observed in 9 of 10 normal tissues and in 3 of 10 
xenografted tissues (Table 4.4). In most cases, xenografted tissues exhibited interrupted 
staining patterns. 
Table 4.4: Immunohistochemical Scoring of Human Vaginal Mucosa for Cytokeratin 14. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. Mouse anti-
human monoclonal antibody raised against cytokeratin 14 antigens was used in both tissues. 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue 
NCL-LL002CK14 Ab 
Xenografted Vaginal Tissue 
NCL-LL002CK14 Ab 
15392/06 4 3 
15396/06 4 4 
16173/06 3 3 
16175/06 4 3 
16176/06 4 4 
8960/06 4 2 
8961/06 4 3 
10156/06 4 4 
17559/06 4 1 
17560/06 4 3 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-LL002CK14 - Reference Code for Human Cytokeratin 14 Antibody; Ab - Antibody. 
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4.4.2 Statistical Comparisons of Cytokeratin 14 Staining Intensities 
Mean staining intensities for cytokeratin 14 in NVT, XVT, NVTα and XVTα were 
3.9±0.1000, 3.0±0.3333, 4.0±0.0000 and 4.0±0.0000, respectively (Figure 4.7). Repeated-
measures one-way ANOVA with subsequent Friedman’s test (Friedman Statistic=18.55) 
indicated significant differences in the mean staining intensities between tissue groups 
(P=0.0003). Conversely, further analysis with Dunn’s multiple comparison test, showed no 
statistical differences in the staining intensities between tissue groups (P>0.05)  
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Figure 4.7: Mean Cytokeratin 14 Staining Intensity by Vaginal Mucosal Type. Data is expressed 
as mean ± standard error of mean (n=10). Friedman’s test indicates a statistical difference between 
tissue types (P=0.0003). On the contrary, Dunn’s post test does not show any statistical difference 
between tissue types (P>0.05).  
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work. 
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4.4.3 Photomicrographs of Vaginal Mucosae Stained for Cytokeratin 14 
  
  
 
Figure 4.8. Immunohistochemical Staining of Cytokeratin 14 on Vaginal Mucosal Tissues. CK14 
staining performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal tissues. Small 
arrows point to cells expressing CK14. Big arrow points to the basal epithelial layer where CK14 is mostly 
localized. Ep-Epithelium; BM-Basement Membrane; CT-Connective Tissue. (Magnifications X100). 
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4.5 COLLAGEN TYPE IV EXPRESSION PROFILE 
4.5.1 Immunohistochemical Scores for Collagen IV 
Human collagen IV was moderately expressed along the basement membrane in 8 of 10 
normal tissues (Table 4.5). Limited or absent human collagen IV staining patterns were 
observed along the basement of xenografted tissues. In addition, positive staining was also 
noted around blood vessels in both normal and xenografted tissues (Figure 4.10). Only 3 of 
10 xenografted tissues stained positively for mouse collagen IV whereas the other 7 tissues 
stained negatively (Table 4.5). 
Table 4.5: Immunohistochemical Scoring of Human Vaginal Mucosa for Collagen IV. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. The 
following collagen IV antibodies were used (a) Mouse anti-human monoclonal Ab; (b) Mouse anti-human 
monoclonal Ab; and (c) Rabbit anti-mouse monoclonal Ab. 
 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue Xenografted Vaginal Tissues 
(A) NCL-COLL-IV Ab (B) NCL-COLL-IV Ab (C) C7510-50S Ab 
15392/06 1 0 1 
15396/06 1 1 0 
16173/06 2 1 1 
16176/06 2 1 0 
8961/06 2 1 1 
8926/06 2 1 0 
10156/06 2 2 0 
10159/06 2 0 0 
17560/06 2 0 0 
10501/06 2 1 2 
*Scoring System; 0-Negative Staining; 1-Rare Positive Staining; 2-Rare Interrupted Positive Staining; 3-Strong Uniform 
Positive Staining. 
NCL-COLL-IV - Reference Code for Human Collagen IV; C7510-50S - Reference Code for Mouse Collagen IV; Ab - 
Antibody. 
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4.5.2 Statistical Comparisons of Collagen IV Staining Intensities 
Mean staining intensities for collagen IV in NVT, XVT-h and XVT-m were 1.8±0.1333, 
0.8±0.2000 and 0.5±0.2236, respectively. Mean staining intensities in NVTα and XVTα-h and 
XVTα-m were 1.4±0.1633, 0.7±0.1528 and 0.6±0.1757, respectively. Repeated-measures 
one-way ANOVA with subsequent Friedman’s test (Friedman Statistic=16.79) indicated 
significant differences between the mean staining intensities between the tissue groups 
(P≤0.0049). Further statistical analysis with Dunn’s multiple comparison test showed no 
statistical differences in the mean staining intensities between the tissue groups (P>0.05). 
Collagen IV Mean Staining Intensities
Tissue Types
St
ai
ni
ng
 In
te
ns
ity
NVT XVT - h XVT - m NVTα XVTα - h XVTα - m
0
1
2
3
4
5
Figure 4.9: Mean Collagen IV Staining Intensity by Vaginal Mucosal Type. Data is expressed as 
mean ± standard error of mean (n=10). Friedman’s test indicates a statistical difference between 
tissue types (P=0.0049). Conversely, Dunn’s post test does not show any statistical difference 
between tissue types (P>0.05).  
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work; h- Human Antigen 
Localization; m-Mouse Antigen Localization. 
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4.5.3 Photomicrographs of Vaginal Mucosae Stained for Human Collagen IV 
  
  
 
Figure 4.10. Immunohistochemical Staining of Human Collagen IV on Vaginal Mucosal Tissues. 
Collagen IV staining performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal 
tissues. Small arrows point to cells expressing collagen IV. Stars indicate that collagen IV is strongly 
expressed along the basement membrane and some blood vessels. Ep-Epithelium; BM-Basement 
Membrane; CT-Connective Tissue; BVs-Blood Vessels. (Magnifications X100 for A, B, C and X200 for D). 
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4.5.4 Photomicrographs of Human and Murine Tissues Stained for Mouse Collagen IV 
 
 
 
Figure 4.11. Immunohistochemical Staining of Mouse Collagen IV on Human and Murine Tissues. 
Collagen IV staining performed on (A) positive control - mouse kidney tissue (B) and (C) xenografted 
vaginal tissues. Stars indicate negative expression of mouse collagen IV along the basement membrane. 
PCT-Proximal Convoluted Tubules; DCT-Distal Convoluted Tubules; Ep-Epithelium; CT-Connective 
Tissue; BVs-Blood Vessels. (Magnifications X100 for A, B and X200 for C). 
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4.6 LAMININ EXPRESSION PROFILE 
4.6.1 Immunohistochemical Scores for Laminin 
Human laminin was staining patterns were varied in both normal and xenografted vaginal 
tissues. The basement membrane and blood vessels exhibited positive staining of human 
laminin (Figure 4.13). Positive staining of human laminin was reported in 6 of 10 normal 
tissues and 7 of 10 xenografted tissues. A weak positive staining of mouse laminin was noted 
in only 2 of 10 xenografted tissues (Table 4.6). 
Table 4.6: Immunohistochemical Scoring of Human Vaginal Mucosa for Laminin. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. The 
following laminin antibodies were used (a) Mouse anti-human monoclonal Ab; (b) Mouse anti-human 
monoclonal Ab; and (c) Rabbit anti-mouse monoclonal Ab. 
 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue Xenografted Vaginal Tissues 
(A) NCL-LAMININ Ab (B) NCL-LAMININ Ab (C) LS-C25107 Ab 
15392/06 1 1 0 
15396/06 2 1 0 
16173/06 2 1 1 
16176/06 0 0 0 
8961/06 0 0 0 
8926/06 0 0 0 
10156/06 0 1 0 
10159/06 2 1 1 
17560/06 3 2 0 
10501/06 3 1 0 
*Scoring System; 0-Negative Staining; 1-Rare Positive Staining; 2-Rare Interrupted Positive Staining; 3-Strong Uniform 
Positive Staining. 
NCL-LAMININ - Reference Code for Human Laminin Antibody; LS-C25107 - Reference Code for Mouse Laminin; Ab - 
Antibody. 
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4.6.2 Statistical Comparisons of Laminin Staining Intensities 
Mean staining intensities for laminin in NVT, XVT-h and XVT-m were 1.3±0.3958, 
0.8±0.2000 and 0.2±0.1470, respectively. Mean staining intensities in NVTα and XVTα-h and 
XVTα-m were 1.3±0.3000, 0.7±0.2134 and 0.0±0.0000, respectively. Repeated-measures 
one-way ANOVA with subsequent Friedman’s test (Friedman Statistic=22.59) indicated 
significant differences in the mean staining intensities between tissue groups (P=0.0004). 
Further statistical analysis with Dunn’s multiple comparison test showed no statistical 
differences in the mean staining intensities between all tissue groups (P>0.05), with an 
exception for NVT and XVTα (P<0.05). 
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Figure 4.12: Mean Laminin Staining Intensity by Vaginal Mucosal Type. Data is expressed as 
mean ± standard error of mean (n=10). Friedman’s test indicates that tissue types are significantly 
different (P=0.0004). Dunn’s multiple test specifies tissue types that are statistically different 
(P<0.05) as denoted by similar alphabets. 
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work; h-Localization of 
Human Antigens; m-Localization of Mouse Antigens. 
*Significant 
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4.6.3 Photomicrographs of Vaginal Mucosae Stained for Human Laminin 
  
  
 
Figure 4.13. Immunohistochemical Staining of Human Laminin on Vaginal Mucosal Tissues. Laminin 
staining performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal tissues. Small 
arrows point to cells expressing laminin. Stars indicate that laminin is strongly expressed along the basement 
membrane and some blood vessels. Ep-Epithelium; BM-Basement Membrane; CT-Connective Tissue; BVs-
Blood Vessels. (Magnifications X100 for A, C and X200 for B, D). 
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4.6.4 Photomicrographs of Human and Murine Tissues Stained for Mouse Laminin 
 
 
 
Figure 4.14. Immunohistochemical Staining of Mouse Laminin on Human and Murine Tissues. 
Laminin staining performed on (A) positive control - mouse kidney tissue (B) and (C) xenografted vaginal 
tissues. Stars indicate negative expression of mouse laminin along the basement membrane. PCT-Proximal 
Convoluted Tubules; DCT-Distal Convoluted Tubules; Ep-Epithelium; CT-Connective Tissue. 
(Magnifications X100 for A, B and X200 for C). 
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4.7 HUMAN ELASTIN EXPRESSION PROFILE 
4.7.1 Immunohistochemical Scores for Elastin 
A strong and well defined positive staining of elastin was seen across the stromal layer in 
both normal and xenografted vaginal tissues (Figure 4.16). Positive elastin staining was also 
observed along the basement membrane of some tissues. Interestingly, positive staining was 
reported in 8 of 10 normal tissues whereas 10 of 10 xenografted tissues stained positively 
(Table 4.7). 
Table 4.7: Immunohistochemical Scoring of Human Vaginal Mucosa for Elastin. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. Mouse anti-
human monoclonal antibody raised against elastin antigens was used in both tissues. 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue 
NCL-ELASTIN Ab 
Xenografted Vaginal Tissue 
NCL-ELASTIN Ab 
15392/06 4 3 
15396/06 3 3 
16173/06 4 4 
16175/06 3 4 
16176/06 3 3 
8960/06 3 3 
8961/06 3 4 
10156/06 4 4 
17559/06 0 4 
17560/06 0 3 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-ELASTIN - Reference Code for Human Elastin Antibody; Ab - Antibody. 
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4.7.2 Statistical Comparisons of Elastin Staining Intensities 
Mean staining intensities for elastin in NVT, XVT, NVTα and XVTα were 2.7±0.4726, 
3.5±0.1667, 4.0±0.0000 and 3.9±0.1000, respectively. Repeated-measures one-way ANOVA 
with subsequent Friedman’s test (Friedman Statistic=14.78) indicated significant differences 
in the mean staining intensities of the tissue groups (P=0.0020). Further statistical analysis 
with Dunn’s multiple comparison test showed no statistical differences between the tissue 
groups (P>0.05). 
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Figure 4.15: Mean Elastin Staining Intensity by Vaginal Mucosal Type. Data is expressed as the 
mean ± standard error of mean (n=10). Friedman’s test indicates that tissue types are significantly 
different (P=0.0020). However, Dunn’s multiple comparison test indicates that tissue types are not 
significantly different (P>0.05). 
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Upublished Work. 
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4.7.3 Photomicrographs of Vaginal Mucosae Stained for Human Elastin 
  
  
 
Figure 4.16. Immunohistochemical Staining of Human Elastin on Vaginal Mucosal Tissues. Elastin 
staining performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal tissues. Small 
arrows indicate a positive and uniformly stained connective tissue. Stars indicate that elastin is also 
expressed along the basement membrane of some vaginal tissues. Ep-Epithelium; BM-Basement Membrane; 
CT-Connective Tissue; BVs-Blood Vessels. (Magnifications X100 for A, B, C and X200 for D). 
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4.8 FIBRONECTIN EXPRESSION PROFILE 
4.8.1 Immunohistochemical Scores for Fibronectin 
A weak to moderate positive staining of human fibronectin was observed along the basement 
membrane and connective tissue in normal and xenografted tissues (Figure 4.18). Positive 
staining was reported in all normal tissues and in 7 of 10 xenografted tissues. Negative 
staining of mouse fibronectin was reported in 8 of 10 xenografted tissues whereas the other 2 
tissues exhibited weak and moderate staining (Table 4.8). 
Table 4.8: Immunohistochemical Scoring of Human Vaginal Mucosa for Fibronectin. Scores reflect the 
difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. The 
following fibronectin antibodies were used (a) Mouse anti-human monoclonal Ab; (b) Mouse anti-human 
monoclonal Ab; and (c) Rabbit anti-mouse monoclonal Ab. 
 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue Xenografted Vaginal Tissues 
(A) NCL-FIB Ab (B) NCL-FIB Ab (C) F4215-46 Ab 
15392/06 1 0 0 
15396/06 1 1 0 
16173/06 2 1 2 
16176/06 2 1 0 
8961/06 2 1 0 
8926/06 2 1 0 
10156/06 2 2 1 
10159/06 2 0 0 
17560/06 2 0 0 
10501/06 2 1 0 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-FIB - Reference Code for Human Fibronectin Antibody; F4215-46 - Reference Code for Mouse Fibronectin Antibody; 
Ab - Antibody. 
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4.8.2 Statistical Comparisons of Fibronectin Staining Intensities 
Mean staining intensities for fibronectin in NVT, XVT-h and XVT-m were 1.8±0.1333, 
0.8±0.2000 and 0.3±0.2134 respectively. Mean staining intensities for NVTα and XVTα-h and 
XVTα-m were 4.0±0.0000, 4.0±0.0000 and 0.0±0.0000 respectively. Repeated-measures one-
way ANOVA with subsequent Friedman’s test (Friedman Statistic=47.27) indicated 
significant differences in the mean staining intensities between tissue groups (P<0.0001). 
Further statistical analysis with Dunn’s multiple comparison test showed slight significant 
differences between NVTα and XVT-h and between XVT-h and XVTα-h (P<0.05).  A high 
statistical difference (P<0.05) was reported between the following tissue groups; NVTα and 
XVT-m, XVT-m and XVTα-h, NVTα and XVTα-m as well as XVTα-h and XVTα-m. 
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Figure 4.17: Mean Fibronectin  Staining Intensity by Vaginal Mucosal Type.  Data is expressed as 
mean ± standard error of mean (n=10) . Friedman’s test indicates that tissue types are significantly 
different (P<0.0001).  Further analysis with Dunn’s post test specifies tissue types that are significantly 
different (P<0.05) as denoted by identical alphabets.  
OVT-Original Vaginal Tissue; X VT-Xenografted  Vaginal Tissue; αCorne Kok-Unpublished Work; h - Human Antigen 
Localization; m-Mouse Antigen Localization.  
*Significant; **Very Significant; ***Extremely Significant  
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4.8.3 Photomicrographs of Vaginal Mucosae Stained for Human Fibronectin 
  
  
 
Figure 4.18. Immunohistochemical Staining of Human Fibronectin on Vaginal Mucosal Tissues. 
Fibronectin staining performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal 
tissues. Small arrows indicate positive and uniformly stained connective tissue. Blood vessels are also 
stained positively. A star denotes positive expression of fibronectin along the basement membrane of that 
particular vaginal tissue. Ep-Epithelium; CT-Connective Tissue; BVs-Blood Vessels. (Magnifications X200 
for A, B, and X400 for C, D). 
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4.8.4 Photomicrographs of Human and Murine Tissues Stained for Mouse Fibronectin 
 
 
 
Figure 4.19. Immunohistochemical Staining of Mouse Fibronectin on Human and Murine Tissues. 
Fibronectin staining performed on (A) positive control - mouse kidney tissue (B) and (C) xenografted 
vaginal tissues. Stars indicate negative expression of mouse fibronectin throughout the connective tissue and 
the epithelium. PCT-Proximal Convoluted Tubules; DCT-Distal Convoluted Tubules; Ep-Epithelium; CT-
Connective Tissue. (Magnifications X200 for A, C and X400 for B). 
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4.9 LANGERHANS CELLS EXPRESSION PROFILE 
4.9.1 Immunohistochemical Scores for Langerhans Cells 
Staining patterns observed for human Langerhans cells (LCs) were varied in both normal and 
xenografted tissues. Positive staining of human LCs was scattered across the epithelium, 
particularly on the basal and parabasal layers (Figure 4.21). Human LCs were positively 
expressed in all normal tissues. In general, xenografted tissues stained positively for LCs, 
with only 3 of 10 tissues having stained negatively. Mouse LCs were negatively stained in 8 
of 10 xenografted tissues (Table 4.9) 
Table 4.9: Immunohistochemical Scoring of Human Vaginal Mucosa for Langerhans Cells. Scores reflect 
the difference in the staining intensity between normal vaginal tissues and xenografted vaginal tissues. The 
following antibodies were used (A) Mouse anti-human monoclonal Ab; (B) Mouse anti-human monoclonal Ab; 
and (C) Rabbit anti-mouse monoclonal Ab. 
 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue Xenografted Vaginal Tissues 
(A) NCL-CD1A-235 Ab (B) NCL-CD1A-235 Ab (C) LS-C735 Ab 
15392/06 4 0 0 
15396/06 4 3 1 
16173/06 4 2 1 
16176/06 1 1 0 
8961/06 1 1 0 
8926/06 2 3 0 
10156/06 2 0 0 
10159/06 1 0 0 
17560/06 1 3 0 
10501/06 1 1 0 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-CD1A-235 - Reference Code for Human Langerhans Cells Antibody; LS-C735 - Reference Code for Mouse 
Langerhans Cells Antibody; Ab - Antibody. 
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4.9.2 Statistical Comparisons of Langerhans Cells’ Staining Intensities 
Mean staining intensities for Langerhans cells in NVT, XVT-h and XVT-m were 2.1±0.4333, 
1.4±0.4000 and 0.2±0.1333, respectively. Mean staining intensities for NVTα, XVTα-h and 
XVTα-m were 4.0±0.0000, 0.3±0.1528 and 0.0±0.0000, respectively. Repeated-measures 
one-way ANOVA with subsequent Friedman’s test (Friedman Statistic=40.55) indicated 
significant differences in the mean staining intensities between the tissue groups (P<0.0001). 
Further statistical analysis with Dunn’s multiple comparison test showed significant 
differences between NVT and XVT-m and between NVT and XVTα-m (P<0.05). A moderate 
significant difference was reported between NVTα and XVTα-h (P<0.05). A high statistically 
significant difference was reported between; NVTαand XVT-m, NVTα and XVTα-m 
(P<0.05). 
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Figure 4.20: Mean Langerhans Cells Staining Intensity by Vaginal Mucosal Type. Data is 
expressed as mean ± standard error of mean (n=10). Friedman’s test indicates that tissue types are 
significantly different (P<0.0001). Further analysis with Dunn’s post test specifies tissue types that 
are significantly different (P<0.05) as denoted by similar alphabets. 
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work; h- Human Antigen 
Localization; m-Mouse Antigen Localization. 
*Significant; **Very Significant; ***Extremely Significant 
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4.9.3 Photomicrographs of Vaginal Mucosae Stained for Human Langerhans Cells 
  
  
 
Figure 4.21. Immunohistochemical Staining of Human Langerhans Cells on Vaginal Mucosal Tissues. 
Langerhans cells staining performed on (A) and (B) normal vaginal tissues. (C) and (D) xenografted vaginal 
tissues. Small arrows point to positively expressed LCs along the epithelium. Big arrow points to a strong 
and uniformly stained basal epithelial layer of this particular normal tissue. Ep-Epithelium; BM-Basement 
Membrane; CT-Connective Tissue; BVs-Blood Vessels. (Magnifications X100 for A and X200 for B, C, D). 
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4.9.4 Photomicrographs of Human and Murine Tissues Stained for Mouse Langerhans Cells 
 
  
 
Figure 4.22. Immunohistochemical Staining of Mouse Langerhans Cells on Human and Murine 
Tissues. Langerhans cell staining performed on (A) and (B) normal vaginal tissues. (C) xenografted vaginal 
tissues. A star indicates that LCs are negatively expressed along the epithelium. Ep-Epithelium; CT-
Connective Tissue. (Magnifications X100 for B, C and X200 for A). 
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4.10 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 
EXPRESSION PROFILE 
4.10.1 Immunohistochemical Scores for VEGFR 
Human VEGFR-3 did not show any obvious cytoplasmic staining reaction in all tissues. 5 of 
10 normal tissues showed a very weak scattered positivity on some areas of the connective 
tissue whereas the other 5 normal tissues were completely negative. 9 of 10 xenografted 
tissues stained negatively for human VEGRF-3. All xenografted tissues displayed absolutely 
no reactivity for mouse VEGFR-2 (Table 4.10).  
Table 4.10: Immunohistochemical Scoring of Human Vaginal Mucosa for VEGFR-3 and VEGFR-2. 
Scores reflect the difference in the staining intensity between normal vaginal tissues and xenografted vaginal 
tissues. The following antibodies were used (A) Mouse anti-human monoclonal Ab raised against VEGFR-3; 
(B) Mouse anti-human monoclonal Ab raised against VEGFR-3; and (C) Rabbit anti-mouse monoclonal Ab 
raised against VEGFR-2. 
 
Tissue Reference No. 
Immunohistochemical Score 
Normal Vaginal Tissue Xenografted Vaginal Tissues 
(A) NCL-L-VEGFR-3 Ab (B) NCL-L-VEGFR-3 Ab (C) V2110-17C2 Ab 
15392/06 1 0 0 
15396/06 1 0 0 
16173/06 1 0 0 
16176/06 1 0 0 
8961/06 1 0 0 
8926/06 0 0 0 
10156/06 0 1 0 
10159/06 0 0 0 
17560/06 0 0 0 
10501/06 0 0 0 
*Scoring System; 0-Negative Staining; 1-Poor Staining (10-25%); 2-Rare Positive Staining (25-50%); 3-Some Positive 
Staining (50-75%); 4-Strong Uniform Positive Staining (>75%). 
NCL-L-VEGFR-3 - Reference Code for Human VEGFR-3 Antibody; V2110-17C2 - Reference Code for Mouse VEGFR-2 
Antibody; Ab - Antibody. 
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4.10.2 Statistical Comparisons of VEGFR Staining Intensities 
Mean staining intensities for VEGFR-3 in NVT, XVT-h, NVTα and XVTα-h were 
0.5±0.1667, 0.1±0.1000, 0.0±0.0000 and 0.0±0.0000, respectively. Mean staining intensities 
for VEGFR-2 in XVT-m and XVTα-m were both 0.0±0.0000. Repeated-measures one-way 
ANOVA with subsequent Friedman’s test (Friedman Statistic=20.00) showed significant 
differences in the mean staining intensities between the tissue groups (P=0.0012). However, 
according to Dunn’s multiple comparison test, there were no statistically significant 
differences between the tissue groups (P>0.05). 
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Figure 4.23: Mean VEGFR-3 and VEGFR-2 Staining Intensity by Vaginal Mucosal Type. Data 
is expressed as mean ± standard error of mean (n=10). Friedman’s test indicates a statistical 
difference between tissue types (P=0.0012). Conversely, Dunn’s post test does not show any 
statistical difference between tissue types (P>0.05).  
NVT-Normal Vaginal Tissue; XVT-Xenografted Vaginal Tissue; αCorne Kok-Unpublished Work; h-Localization of 
Human VEGFR-3 Antigens; m-Localization of Mouse VEGFR-2 Antigens. 
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4.10.3 Photomicrographs of Vaginal Mucosae Stained for VEGFR 
  
  
 
Figure 4.24. Immunohistochemical Staining of VEGFR-3 and VEGFR-2 on Human Vaginal Mucosal 
Tissues. VEGFR-3 staining performed on (A) normal and (B) xenografted vaginal tissues. VEGFR-2 
staining performed on (C) normal and (D) xenografted vaginal tissues. Small arrows point to negatively 
expressed VEGFR along the epithelium, the connective tissue and around blood vessels. Big arrow points to 
a light positive staining of VEGFR-3 on the connective tissue. Ep-Epithelium; CT-Connective Tissue; BVs-
Blood Vessels. (Magnifications X200 for B, C, D and X400 for A). 
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CHAPTER FIVE 
DISCUSSION AND CONCLUSION 
As already stated, there is only one immunohistochemical study of the biocyst model 
proposed by Thompson et al., [4] Therefore our results will be discussed in relation to that 
one immunohistochemical work done by Kok [6]. The ultimate goal of this chapter was to 
use data obtained to elucidate the nature of the epithelium, the basement membrane (BM) and 
stromal layer that had formed between the xenografted epithelial cyst and its surrounding 
mouse tissue. 
5.1 INTERPRETATION OF RESULTS 
5.1.1 Analysis of Cytokeratin 1 Expression Profile 
Cytokeratin 1 (CK1) is a large keratin isotype of 68 kDa found in complex epithelia [96]. We 
firstly evaluated the expression pattern of human CK1 in NVTs and XVTs. CK1 was stained 
with mouse anti-CK1 primary antibody that reacts with squamous epithelia. 
We observed in all NVTs, strong positively stained epithelial cells, particularly at the 
superficial and intermediate epithelial layers. In XVTs, the expression pattern of CK1 was 
either absent or moderate. Although our findings are consistent with those of the previous 
study, there is an interesting difference. Kok reported negative staining in most experimental 
cysts with a thin epithelium and positive staining in cysts with a thick epithelium [6]. In our 
study, the observed expression of CK1 was not well defined, nor was it different in XVTs 
with a thin or thick epithelium. Statistical analysis with Dunn’s post test revealed significant 
differences between the staining intensity of NVTs, XVTs, NVTα and XVTα (P>0.05). It 
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therefore appears that a loss of CK1 occurred either during transplantation process or while 
xenografted vaginal tissues were in a mouse environment. 
5.1.2 Analysis of Cytokeratin 5 Expression Profile 
Cytokeratin 5 (CK5) is 58 kDa intermediate filament protein of the basal epithelial layer of 
various tissues [97, 98]. CK5 is considered a marker of basal epithelial cells and 
myoepithelial cells of normal breast tissue. In addition, it has been reported as a progenitor 
cell marker in neoplastic tissues [97, 99].We evaluated the expression of human CK5 by 
staining tissues with mouse anti-CK5 monoclonal antibody. 
The epithelium was considered positive when distinct cytoplasmic staining was present. The 
epithelium exhibited CK5 positive material in both NVTs and XVTs. Positive reaction of 
CK5 was localized to the parabasal and basal epithelial layers. CK5 staining was well defined 
and uniformly distributed in NVTs. Conversely, some XVTs exhibited occasional 
interruptions in the staining patterns observed. Similarly, Kok also reported even and uneven 
staining in NVTs and XVTs respectively. Despite qualitative differences in the staining 
patterns between NVTs and XVTs, statistical analysis with Dunn’s post test revealed no 
significant differences between NTVs, XVTs, NVTα and XVTα (P>0.05). 
5.1.3 Analysis of Cytokeratin 13 Expression Profile 
Cytokeratin 13 (CK13) is an acidic intermediate filament protein of 54 kDa. It is the primary 
constituent of squamous, non-keratinized epithelium, transitional epithelium and 
pseudostratified epithelium. CK13 is often used as a marker of various epithelium-derived 
cancers [100]. Human CK13 was stained with mouse anti-CK13 monoclonal antibody. 
Data presented herein indicates positive staining of CK13 in both NVTs and XVTs (Table 
4.3). Positive staining was predominantly localized to the parabasal epithelial layer. In some 
tissues, positive staining of the BM was also noticed. Moreover, the staining intensity seen in 
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NVTs was greater than that exhibited by XVTs. This contradicts findings of previous work, 
in which a similar strong uninterrupted staining was reported in all vaginal tissues. 
Nevertheless, further statistical comparisons demonstrate no significant differences in the 
mean staining intensities between NVTs, XVTs, NVTα and XVTα (P>0.05).Therefore, we 
can confidently state that, although slight differences in the expression patterns between 
NVTs and XVTs were observed, human CK13 was indeed retained in a murine environment. 
5.1.4 Analysis of Cytokeratin 14 Expression Profile 
Cytokeratin 14 (CK14) is a member of the family of acidic type I cytokeratins [101] 
expressed by myoepithelial cells [102]. CK14 is expressed in the basal layer of stratified 
squamous and non-squamous epithelia [101, 103]. Human CK14 was stained with LL002, a 
sensitive monoclonal antibody that can distinguish stratified epithelial cells from simple 
epithelial cells. 
CK14 was detected as cytoplasmic staining in the basal epithelial layer of vaginal tissues. 
Intense positive expression of CK14 was reported in all NVTs and XVTs. Statistical 
comparisons revealed no significant differences between NVTs, XVTs, NVTα and XVTα 
(P>0.05). A relatively strong expression of CK14 in both NVTs and XVTs reflects that this 
human marker is entirely maintained in a murine environment. 
5.1.5 Analysis of Collagen Type IV Expression Profile 
The ECM plays a critical role in cell migration, proliferation and differentiation [21, 45] 
Degradation of the ECM is implicated in many physiological and pathological conditions. 
ECM degradation is characterized by several factors, including a reduction of collagen and 
elastin fiber networks. In this section, we also explored whether or not transplantation leads 
to a loss of collagen IV, the major constituent of BMs. Tissues were stained with mouse anti-
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human antibodies and rabbit anti-mouse antibodies that recognize human and mouse collagen 
IV respectively. The antibodies react positively with the BM. 
We report diffuse positive expression of human collagen IV along the BM and blood vessels 
in 10/10 NVTs and 7/10 XVTs (Table 4.5). Strong staining with occasional interruptions was 
noted in NVTs whereas XVTs presented thin staining patterns of human collagen IV. This 
coincides with data of Kok’s study. Limited human collagen IV staining in XVTs could be 
due to injury incurred by the BM when the epithelium was separated from the underlying 
connective tissue during construction of cysts. Although mice that were used to host tissues 
were immune-deficient, they may still be other murine factors that contributed to a loss of 
human collagen IV in XVTs. Limited or absent staining of mouse collagen IV was also 
observed along the BM of XVTs. Interestingly, mouse collagen IV staining was not evident 
around blood vessels of XVTs that had stained positively along the BM. Statistical analysis 
shows no significant differences in the expression patterns of human collagen IV and mouse 
collagen IV in all vaginal tissues. Our statistical data therefore suggests no significant loss of 
human collagen IV after transplantation. 
5.1.6 Analysis of Laminin Expression Profile 
Like collagen IV, laminin is also one of the major constituents of the BM [21, 22, 48]. This 
large disulphide-bonded glycoprotein also occurs in the ECM, at sites other than the BM 
during early stages of development. Several studies have demonstrated that laminin is highly 
expressed in BMs of different human tissues [55]. In this section, we also examined the 
extent to which laminin is expressed by the BM of vaginal tissues. 
As expected, human laminin was present along the BM of NVTs and XVTs. Blood vessels 
along the stromal layer also exhibited laminin positive material. Expression patterns of 
human laminin in NVTs and XVTs were relatively low to moderate. A very weak staining of 
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mouse laminin was observed in only 2 XVTs. Similarly, Kok also reported low to moderate 
expression of human laminin and negatively expressed mouse laminin. It also appears that 
damage to the BM could be responsible for these findings. Furthermore, our data is not 
consistent with published studies in which a high expression of laminin was reported [55]. 
This contrast could be that human tissues assessed in those studies were different from 
vaginal tissues and had neither been xenografted into mice. The statistical test revealed no 
significant differences in the staining intensities between all tissues (P>0.05). 
5.1.7 Analysis of Elastin Expression Profile 
Elastin is a polymeric protein and a major constituent of the ECM. It is a principal protein of 
elastic fibers that imparts elasticity to several tissues. Several literature reports indicate that 
elastin can change its morphology during ageing and different disease states [62, 63, 65, 66] 
Here, we also investigated whether or not elastic fibers of vaginal tissues remain unchanged 
after transplantation. 
Data presented herein indicates an intense positive staining of elastic fibers in both NVTs and 
XVTs. Positive staining was densely distributed across the stromal layer. In some tissues, 
positive staining of the BM was also noted. Interestingly, positive staining occurred in all 
XVTs, but in 8/10 NVTs. In addition, the staining intensity seen in XVTs was higher than 
that exhibited by NVTs. It is therefore suggested that increased elastin may be a secondary or 
reactive production of elastin by stromal cells adjacent to the cyst. This contradicts findings 
of the previous study, in which strong uniform staining was reported in all NVTα and XVTα. 
This discrepancy could not be explained. Nevertheless, further statistical comparisons 
demonstrate no significant differences between NVTs, XVTs, NVTα and XVTα (P>0.05). 
Therefore, we can confidently state that, elastic fibers do indeed remain the same after 
transplantation. 
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5.1.8 Analysis of Fibronectin Expression Profile 
Fibronectin (FN) is a major adhesion glycoprotein that promotes interaction between 
epithelial cells and the ECM [67]. Vaginal tissues were stained with mouse anti-human 
antibodies and rabbit anti-mouse antibodies that recognize human and mouse FN 
respectively. The antibodies react positively with the connective tissue matrix. 
Positive FN reaction was identified as brown cordlike and reticular structures along the BM, 
the stromal layer and around blood vessels. A moderate positive reaction of human FN was 
detected in NVTs and XVTs. None of the tissues reacted positively for mouse FN. These data 
are consistent with Kok’s findings. The staining patterns reported for NVTs, XVTs, NVTα 
and XVTα were statistically different (P<0.05). 
5.1.9 Analysis of Langerhans Cells Expression Profile 
Langerhans cells (LCs) are a group of antigen presenting cells of bone marrow origin which 
mainly reside on basal and suprabasal epithelial layers [104]. LCs are highly effective and 
play a vital role in the regulation of immune surveillance of mucosal barriers [13, 78]. 
Epidermal LCs can be identified using a number of markers. Accurate identification of LCs 
requires stable markers that are uniquely expressed on LCs [105]. Such markers include 
OKT6, Leu6 and CD1a. A positive staining reaction with such markers is regarded as the 
‘gold standard’ for the identification of LCs [106]. CD1a is considered an exceptional 
marker, because unlike other markers, it stains both the dendrites and Birbeck granules 
contained within a cell body [105]. Several studies often use CD1a for the quantification of 
LCs in various human tissues. Therefore, in this study, human LCs were stained with CD1a. 
Mouse LCs were stained with Langerin (CD207). 
Human LCs were detected as CD1a-positive brown stained cells in all NVTs and XVTs. 
Positively expressed human LCs with defined dendrites were localized to the basal and 
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suprabasal epithelial layers. Mouse LCs were negatively expressed in 8/10 tissues. Strikingly, 
when mouse skin was used as a positive control and stained with Langerin, the result 
remained negative despite attempts to optimize the experiment. Such an observation raises 
the question why mouse LCs were not functional. A weak positive staining observed in 2 
XVTs may have been a false-positive result. Statistical comparisons revealed significant 
differences between the staining intensities of NVTs, XVTs, NVTα and XVTα (P<0.05). It 
appears that human LCs are not entirely sustained in a murine environment because their 
expression was greater in NVTs than XVTs. A well-defined dendritic morphology of human 
LCs observed in NVTs could reflect optimal immune surveillance of vaginal tissue prior to 
transplantation. 
5.1.10 Analysis of Vascular Endothelial Growth Factor Receptor 
Expression Profile 
Lymphatic vasculature plays a critical role in tumor metastasis, and as such, the mechanisms 
that regulate the growth of lymphatic vessels have become an attractive field in cancer 
research. VEGFR-3 is a key receptor for lymphangiogenic factors VEGF-C and VEGF-D. 
Emerging data indicates that VEGFR-3 contributes to angiogenesis, and hence its use as a 
marker for lymphatic vessels in several studies [107]. VEGFR-2 is a cell membrane receptor 
kinase expressed by endothelial cells and hematopoietic cells. VEGFR-2 is the main mediator 
of VEGF-A biological activity is actively involved in embryonic angiogenesis and 
hematopoiesis [83]. Human VEGFR-3 was stained with mouse anti-human primary antibody 
whereas mouse VEGFR-2 was stained with rabbit anti-mouse primary antibody. 
We observed in 5/10 NVTs, small brown clusters of what appeared to be positively expressed 
VEGFR-3 along the stromal layer. In XVTs, VEGFR-3 was only expressed in one tissue. 
These findings contradict those of the previous study. Although brown clusters that were 
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observed in NVTs were reported as positive staining of VEGFR-3, further statistical analysis 
with Dunn’s post test revealed no significant differences between the staining intensities of 
all tissues (P>0.05). We can therefore say the degree of positivity observed in those NVTs is 
not meaningful to postulate that VEGFR-3 marker was indeed expressed. Furthermore, since 
the staining did not occur around blood vessels as expected, it could have then been false-
positive results. None of the tissues expressed mouse VEGRF-2, and this is coincides with 
the immunohistochemical results of the previous study. 
5.2 CONCLUSION 
This study provides the basis for the characterization of human vaginal tissues that were 
xenografted into athymic nude mice. Immunohistochemical analysis of a panel of human and 
murine markers was performed to determine whether or not the morphology of human 
vaginal epithelium is retained after transplantation into a murine environment. The ultimate 
goal was to determine the nature of the stromal layer that had developed between xenografted 
cysts and mouse tissues. 
Firstly, given that human cytokeratins were positively and strongly expressed on the 
epithelium of xenografted tissues, we can confidently state that the epithelium of the 
xenograft was still of human origin. Moreover, positively expressed human Langerhans cells 
and negatively expressed mouse Langerhans cells on the epithelium confirm this statement. 
Morphology of the epithelium is indeed retained despite transplantation into a murine 
environment, thus reaffirming findings of previous work. Secondly, although mouse collagen 
and mouse laminin were positively expressed in a few xenografted tissues, the degree of 
positivity was not as well defined as it was with human collagen IV and human laminin. 
However, there were no statistical differences in the staining intensities between human and 
mouse markers. These data are inconclusive and we can therefore only speculate that the BM 
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is mainly, but not entirely of human origin. Thirdly, human elastin and human fibronectin 
reacted positively with the stromal layer. Only one xenografted tissue reacted positively for 
human VEGRF-3. On the contrary, negative expression of mouse fibronectin and mouse 
VEGRF-2 was reported in most of the xenografted tissues. These expression patterns are very 
different from those of the previous study. According to our data, the stromal layer is of 
human origin. We therefore cannot agree with one of Kok’s conclusions which suggested that 
the stromal layer is a combination of human and murine tissue. However, the fatty-tissue 
muscular layer interface at the periphery of the stroma is indeed a combination of human and 
murine tissue as suggested in the previous study. 
In summary, the concept of ‘cyst transplantation’ is attractive, but it requires continued 
efforts before any definitive conclusions can be made. Currently, little is known about the 
effect that athymic nude mouse environment has on human vaginal cysts. Therefore, more 
information is required to determine physiological changes that occur when human vaginal 
tissues are subjected to a murine environment. 
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CHAPTER SIX 
LIMITATIONS OF THE STUDY AND FUTURE 
PROSPECTS 
6.1 PROBLEMS ENCOUNTERED AND RECOMMENDATIONS 
 The number of experimental cysts was not sufficient because cysts that had been 
ruptured and inflamed were excluded from the study. It is therefore important to 
construct a large number of cysts, to cover for any mishaps. In addition, a large 
number of cysts could provide a more comprehensive statistical data. 
 Staining patterns with some rabbit anti-mouse primary antibodies could not be 
interpreted, making it difficult to award scores. 
 Some slight background staining was noted in a few tissues. Since the antibodies used 
were monoclonal, we can disregard the fact that background staining could be due to 
non-specific antibody binding. We can therefore only suggest that the presence of 
endogenous enzymes was responsible for background staining. Working dilution of 
the antibodies could be increased to address this issue. 
6.2 FUTURE DIRECTIONS 
 We aim to gain further insight into the underlying mechanisms and factors that 
contributed to morphological changes that were observed in the xenografted human 
vaginal tissues. 
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 We intend to implement an in vivo biotest model integrating various human tissue 
types. The different tissues types will be xenografted to investigate whether their 
natural-tissue architecture is retained. 
 Our future objective is to include a large panel of antibodies for each marker in order 
to determine any discrepancies in the expression patterns of human and murine 
markers. 
 In a study by Sivard et al., [80] an in vitro reconstructed vaginal mucosa incorporating 
Langerhans cells was developed. Such an in vitro culture model offers a great 
opportunity for a study that compares fresh human vaginal mucosa with reconstructed 
vaginal mucosa. 
 Athymic nude mouse model provides excellent research opportunities for several 
studies. This model could be used to evaluate protein and gene expression of various 
human tissues using biochemical techniques such as polymerase chain reaction (PCR) 
and Western blot analysis. 
 
 
 
 
88 
REFERENCES 
[1] Morton CL, Houghton PJ: Establishment of Human Tumor Xenografts in Immunodeficient Mice. 
Nature Protocols 2007, 2(2):247-250. 
[2] Yue W, Zhou D, Chen S, Brodie A: A New Nude Mouse Model for Postmenopausal Breast Cancer 
Using MCF-7 Cells Transfected with the Human Aromatase Gene. Cancer Research 1994, 
54:5092-5095. 
[3] Topley P, Jenkins DC, Jessup EA, Stables EN: Effect of Reconstituted Basement Membrane 
Components on the Growth of a Panel of Human Tumour Cell Lines in Nude Mice. British 
Journal of Cancer 1993, 67:953-958. 
[4] Thompson IO, Van Wyk CW, Darling MR: Human Vaginal Epithelium and the Epithelial Lining 
of a Cyst Model Constructed from it: A Comparative Light Microscopic and Electron 
Microscopic Study. South African Dental Journal 2001, 56(11):517-520. 
[5] Wang M: Contamination, Infection and Inflammation Control in an Experimental Mucosal Cyst 
Model using Athymic Nude Mice. MSc Thesis. University of the Western Cape; 2007. 
[6] Kok CW: Molecular Characterization of Human Vaginal Mucosa obtained from Fresh Harvest 
and Implants in an Experimental Nude Mouse Model. MSc Thesis. University of Stellenbosch; 
2010. 
[7] Carroll AR, Coleman RL, Sood AK: Therapeutic Advances in Women's Cancers. Front Bioscience 
2011, 3:82-97. 
[8] Schmied BM, Ulrich AB, Matsuzaki H, El-Metwally TH, Ding X, Fernandes ME, Adrian TE, Chaney 
WG, Batra SK, Pour PM: Biological Instability of Pancreatic Cancer Xenografts in the Nude 
Mouse. Carcinogenesis 2000, 21(6):1121-1127. 
[9] Johansson EL, Rudin A, Wassen L, Holmgren J: Distribution of Lymphocytes and Adhesion 
Molecules in Human Cervix and Vagina. Immunology and Infectious Diseases 1999, 96:272-277. 
[10] Kerbel RS: Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug 
Activity in Humans. Cancer Biology and Therapy 2003, 2(4):134-139. 
[11] Abdul-Karim FW, Somrak TM, Yang B: Chapter 11 - Vulva, Vagina and Anus. In: Comprehensive 
Cytopathology (3rd Edition). Edinburgh: W.B. Saunders; 2008: 273-289. 
[12] Haschek WM, Rousseaux CG, Wallig MA: Chapter 19 - Female Reproductive System. In: 
Fundamentals of Toxicologic Pathology (2nd Edition). San Diego: Academic Press; 2010: 599-631. 
[13] Black CA, Murphy-Corb M: Chapter 30 - Dendritic Cells in the Reproductive Tract. In: Dendritic 
Cells (2nd Edition). London: Academic Press; 2001: 411-421. 
[14] Squier CA, Mantz MJ, Schlievert PM, Davis CC: Porcine Vagina Ex Vivo as a Model for Studying 
Permeability and Pathogenesis in Mucosa. Pharmaceutical Sciences 2008, 97(1):9-21. 
[15] Miller CJ, Shattock RJ: Target Cells in Vaginal HIV Transmission. Microbes and Infection 2003, 
5:59-67. 
[16] Zeng Z, Cohen AM, Guillem JG: Loss of Basement Membrane Type IV Collagen is Associated 
with Increased Expression of Metalloproteinases 2 and 9 (MMP-2 and MMP-9) during Human 
Colorectal Tumorigenesis. Carcinogenesis 1999, 20(5):749-755. 
 
 
 
 
89 
[17] Egeblad M, Rasch MG, Weaver VM: Dynamic Interplay between the Collagen Scaffold and Tumor 
Evolution. Current Opinion in Cell Biology 2010, 22(5):697-706. 
[18] Tanzer ML: Current Concepts of Extracellular Matrix. Orthopaedic Science 2006, 11(3):326-331. 
[19] Sherwood DR: Cell Invasion through Basement Membranes: An Anchor of Understanding. 
Trends in Cell Biology 2006, 16(5):250-256. 
[20] Schwarzbauer J: Basement Membrane: Putting up the Barriers. Current Biology 1999, 9:242-244. 
[21] Kruegel J, Miosge N: Basement Membrane Components are Key Players in Specialized 
Extracellular Matrices. Cellular and Molecular Life Sciences 2010, 67(17):2879-2895. 
[22] LeBleu VS, MacDonald B, Kalluri R: Structure and Function of Basement Membranes. 
Experimental Biology and Medicine 2007, 232(9):1121-1129. 
[23] Chi C, Wang S, Prenter A, Cooper S, Wojnarowska F: Basement Membrane Zone and Dermal 
Extracellular Matrix of the Vulva, Vagina and Amnion: An Immunohistochemical Study with 
Comparison with Non-Reproductive Epithelium. Australasian Journal of Dermatology 2010, 
51:243-247. 
[24] Steukers L, Glorieux S, Vandekerckhove AP, Favoreel HW, Nauwynck HJ: Diverse Microbial 
Interactions with the Basement Membrane Barrier. Trends in Microbiology 2012, 20(3):147-155. 
[25] Wetzels RHW, Robben HCM, Leigh IM, Schaafsma HE, Vooijs GP, Ramaekerst FCS: Distribution 
Patterns of Type VII Collagen in Normal and Malignant Human Tissues. American Journal of 
Pathology 1991, 139(2):451-459. 
[26] Kariya Y, Miyazaki K: The Basement Membrane Protein Laminin-5 Acts as a Soluble Cell 
Motility Factor. Experimental Cell Research 2004, 297(2):508-520. 
[27] Guess CM, Quaranta V: Defining the Role of Laminin-332 in Carcinoma. Matrix Biology 2009, 
28(8):445-455. 
[28] Tzu J, Marinkovich MP: Bridging Structure with Function: Structural, Regulatory, and 
Developmental Role of Laminins. International Journal of Biochemistry and Cell Biology 2008, 
40(2):199-214. 
[29] Ray MC, Gately LE: Basement Membrane Zone. Clinics in Dermatology 1996, 14:321-330. 
[30] Kramer JM: Chapter 1 - Basement Membranes. In: The C elegans Research Community, WormBook. 
Chicago: WormBook; 2005: 1-15. 
[31] Watkins J, Mathieson I: Chapter 4 - Connective tissues. In: The Pocket Podiatry Guide: Functional 
Anatomy. Edinburgh: Churchill Livingstone; 2009: 107-156. 
[32] Hadju SI, Lemos LB, Kozakewich H, Helson L, Beattie EJ: Growth Pattern and Differentiation of 
Human Soft Tissue Sarcomas in Nude Mice. Cancer 1981, 47(1):90-98. 
[33] Sachs DH, Sykes M, Robson SC, Cooper DKC: Xenotransplantation. Advances in Immunology 2001, 
79:129-223. 
[34] Ikeda K, Tate G, Suzuki T, Mitsuya T: Coordinate Expression of Cytokeratin 8 and Cytokeratin 17 
Immunohistochemical Staining in Cervical Intraepithelial Neoplasia and Cervical Squamous Cell 
Carcinoma: An Immunohistochemical Analysis and Review of theLiterature. Gynecologic 
Oncology 2008, 108:598-602. 
[35] Barrett AW, Cort EM, Patel P, Berkovitz BKB: An Immunohistological Study of Cytokeratin 20 in 
Human and Mammalian Oral Epithelium. Archives of Oral Biology 2000, 45:879-887. 
 
 
 
 
90 
[36] Bakhtiar Y, Hirano H, Arita K, Yunoue S, Fujio S, Tominaga A, Sakoguchi T, Sugiyama K, Kurisu K, 
Yasufuku-Takano K et al: Relationship Between Cytokeratin Staining Patterns and Clinico-
Pathological Features in Somatotropinomae. European Journal of Endocrinology 2010, 163:531-
539. 
[37] Barnard K, Gathercole LJ, Bailey AJ: Basement Membrane Collagen - Evidence for a Novel 
Molecular Packing. FEBS Letters 1987, 212(1):49-52. 
[38] Kefalides NA, Zahra Z: Chapter 12 - Connective Tissues and Aging. In: Brocklehurst's Textbook of 
Geriatric Medicine and Gerontology (7th Edition). Philadelphia: W.B. Saunders; 2010: 73-81. 
[39] Ayad S, Boot-Handford R, Humphries MJ, Kadler KE, Shuttleworth A: Chapter 15 - Collagen Type 
IV. In: The Extracellular Matrix Facts Book (2nd Edition). San Diego: Academic Press; 1998: 54-62. 
[40] Davidson B, Goldberg I, Gotlieb WH, Ben-Baruch G, Kopolovica  J: Expression of Matrix Proteins 
in Uterine Cervical Neoplasia using Immunohistochemistry. Obstetrics Gynecology 1998, 76:109-
114. 
[41] Ghohestani RF, Li K, Rousselle P, Uitto J: Molecular Organization of the Cutaneous Basement 
Membrane Zone. Clinics in Dermatology 2001, 19:551-562. 
[42] Kuhn K, Wiedemann H, Timpl R, Risteli J, Dieringer H, Voss T, Glanville RW: Macromolecular 
Structure of Basement Membrane Collagens. FEBS Letters 1981, 125(1):123-128. 
[43] Ray JM, Stetler-Stevenson WG: The Role of Matrix Metalloproteases and their Inhibitors in 
Tumour Invasion, Metastasis and Angiogenesis. Europian Respiratory 1994, 7:2062-2072. 
[44] Vazquez F, Palacios S, Aleman N, Guerrero F: Changes of the Basement Membrane and Type IV 
Collagen in Human Skin during Aging. Climacteric and Postmenopause 1996, 25:209-215. 
[45] Indumathi S, Yin M, Taeyoung K, William K, Jacob R, Rong W: Structural and Mechanical Profiles 
of Native Collagen Fibers in Vaginal Wall Connective Tissues. Biomaterials 2012, 33(5):1520-
1527. 
[46] Hattori K, Mabuchi R, Fujiwara H, Sanzen N, Sekiguchi K, Kawai K, Akaza H: Laminin Expression 
Patterns in Human Ureteral Tissue. Urology 2003, 170(5):2040-2043. 
[47] Hallmann R, Horn N, Selg M, Wendler O, Pausch F, Sorokin LM: Expression and Function of 
Laminins in the Embryonic and Mature Vasculature. Physiological Reviews 2005, 85:976-1000. 
[48] Tsuruta D, Kobayashi H, Imanishi H, Sugawara K, Ishii M, Jones JCR: Laminin-332-Integrin 
Interaction: A Target for Cancer Therapy? Current Medicinal Chemistry 2008, 15(20):1968-1975. 
[49] Cukierman E, Bassi DE: Physico-Mechanical Aspects of Extracellular Matrix Influences on 
Tumorigenic Behaviors. Seminars in Cancer Biology 2010, 20:139-145. 
[50] Liotta LA: Tumor Invasion and Metastases: Role of the Basement Membrane. Warner-Lambert 
Parke-Davis Award Lecture. American Journal of Pathology 1984, 117(3):339-348. 
[51] Botti J, Musset M, Moutsita R, Aubery M, Derappe C: Two Laminin Receptors with N -
Acetylglucosamine-Binding Specificity. Biochimie 2003, 85(1-2):231-239. 
[52] Macdonald PR, Lustig A, Steinmetz MO, Kammerer RA: Laminin Chain Assembly is Regulated by 
Specific Coiled-Coil Interactions. Structural Biology 2010, 170(2):398-405. 
[53] Patarroyo M, Tryggvason K, Virtanen I: Laminin Isoforms in Tumor Invasion, Angiogenesis and 
Metastasis. Cancer Biology 2002, 12(3):197-207. 
 
 
 
 
91 
[54] Sanders EJ: Chapter 5 - The Role of Extracellular Matrix during Development. In: Developmental 
Biology. San Diego: Academic Press; 1998: 89-101. 
[55] Beliard A, Donnez J, Nisolle M, Foidart J: Localization of Laminin, Fibronectin, E-cadherin and 
Integrins in Endometrium and Endometriosis*. Fertility and Sterility 1997, 67(2):266-272. 
[56] Malinda KM, Kleinman HK: The Laminins. Cell Biology 1996, 28(9):957-959. 
[57] Hamill KJ, Paller AS, Jones JCR: Adhesion and Migration, the Diverse Functions of the Laminin 
α3 Subunit. Dermatologic Clinics 2010, 28(1):79-87. 
[58] Ekblom P: Receptors for Laminins During Epithelial Morphogenesis. Current Opinion in Cell 
Biology 1996, 8:700-706. 
[59] Kielty CM, Sherratt MJ, Shuttleworth CA: Elastic Fibres. Cell Science 2002, 115(14):2817-2828. 
[60] Ross R: The Elastic Fiber. Histochemistry and Cytochemistry 1973, 21(3):199-208. 
[61] Hushiki T: Collagen Fibers, Reticular Fibers and Elastic Fibers. A Comprehensive Understanding 
from a Morphological Viewpoint. Archives of Histology and Cytology 2002, 65(2):109-126. 
[62] Mithieux SM, Weiss AS: Elastin. Advances in Protein Chemistry 2005, 70:437-461. 
[63] Rodgers UR, Weiss AS: Cellular Interactions with Elastin. Pathologie Biologie 2005, 53:390-398. 
[64] Sherratt MJ: Tissue Elasticity and the Ageing Elastic Fibre. Age 2009, 31(4):305-325. 
[65] Keeley FW, Bellingham CM, Woodhouse KA: Elastin as a Self-Organizing Biomaterial: Use of 
Recombinantly Expressed Human Elastin Polypeptides as a Model for Investigations of 
Structure and Self-Assembly of Elastin. The Royal Society 2002, 357(1418):185-189. 
[66] Gosline J, Lillie M, Carrington E, Guerette P, Ortlepp C, Savage K: Elastic proteins: biological roles 
and mechanical properties. The Royal Society 2002, 357(1418):121-132. 
[67] Hynes RO, Yamada KM: Fibronectins: Multifunctional Modular Glycoproteins. Cell Biology 1982, 
95:369-377. 
[68] Faralli JA, Schwinn MK, Gonzalez JM, Filla MS, Peters DM: Functional Properties of Fibronectin 
in the Trabecular Meshwork. Experimental Eye Research 2009, 88(4):689-693. 
[69] Pankov R, Kenneth MY: Fibronectin at a Glance. Cell Science 2002, 115(20):3861-3863. 
[70] Romberger DJ: Fibronectin. Cell Biology 1997, 29(7):939-943. 
[71] Liaw L, Crawford HC: Functions of the Extracellular Matrix and Matrix Degrading Proteases 
during Tumor Progression. Brazilian Journal of Medical and Biological Research 1999, 32(1):805-
812. 
[72] Blanco P, Palucka AK, Banchereau J: Chapter 9 - Introduction to Dendritic Cells. In: Gene Therapy 
of Cancer (2nd Edition). San Diego: Academic Press; 2002: 167-177. 
[73] Abbott GF, Rosado-de-Christenson ML, Franks TJ, Frazier AA, Galvin JR: From the Archives of the 
AFIP: Pulmonary Langerhans Cell Histiocytosis. Radiographics 2004, 24(3):821-841. 
[74] Maurer D, Stingl G: Chapter 5 - Langerhans Cells. In: Dendritic Cells (2nd Edition). London: 
Academic Press; 2001: 35-51. 
[75] Romani N, Clausen BE, Stoitzner P: Langerhans Cells and More: Langerin-Expressing Dendritic 
Cell Subsets in the Skin. Immunological Reviews 2010, 234(1):120-141. 
 
 
 
 
92 
[76] Eggert AAO, Otto K, McLellan AD, Terheyden P, Linden C, Kämpgen E, Becker JC: Chapter 12 - 
Generation of Human and Murine Dendritic Cells. In: Cell Biology (3rd Edition). Burlington: 
Academic Press; 2006: 103-112. 
[77] Villadangos JA, Young LJ: Chapter 7 - Antigen-Presenting Cells and Antigen Presentation. In: 
Clinical Immunology (3rd Edition). Edinburgh: Mosby; 2008: 103-111. 
[78] Austyn JM: Chapter 10 - Mobilization, Migration and Localization of Dendritic Cells. In: 
Dendritic Cells (2nd Edition)London: Academic Press; 2001: 131-149. 
[79] Ueno H, Klechevsky E, Palucka AK, Banchereau J: Chapter 19 - Human Dendritic Cell Subsets. In: 
Methods in Microbiology. San Diego: Academic Press; 2010: 497-513. 
[80] Sivard P, Berlier W, Picard B, Sabido O, Genin C, Misery L: HIV-1 Infection of Langerhans Cells in 
a Reconstructed Vaginal Mucosa. Infectious Diseases 2004, 190(2):227-235. 
[81] Shibuya M: Vascular Endothelial Growth Factor-Dependent and -Independent Regulation of 
Angiogenesis. Biology and Molecular Biology Reports 2008:278-286. 
[82] Ferrara N: Vascular Endothelial Growth Factor. Arteriosclerosis, Thrombosis, and Vascular Biology 
2009, 29(6):789-791. 
[83] Karamysheva AF: Mechanisms of Angiogenesis. Biochemistry 2008, 73(7):751-762. 
[84] Kowanetz M, Ferrara N: Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic 
Perspective. Clinical Cancer Research 2006, 12(17):5018-5022. 
[85] Moser C, Lang SA, Stoeltzing O: The Direct Effect of Anti-Vascular Endothelial Growth Factor 
Therapy on Tumor Cells. Clinical Colorectal Cancer 2007, 6(8):564-571. 
[86] Murukesh N, Dive C, Jayson GC: Biomarkers of Angiogenesis and their Role in the Development 
of VEGF Inhibitors. British Journal of Cancer 2009, 102(1):8-18. 
[87] Sullivan LA, Brekken RA: The VEGF Family in Cancer and Antibody-Based Strategies for their 
Inhibition. Landes Bioscience 2010, 2(2):165-175. 
[88] Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE: Integrins: The Keys to Unlocking 
Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28(10):1703-1713. 
[89] Pennell NA, Lynch TJ: Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the 
Treatment of NSCLC. The Oncologist 2009, 14(4):399-411. 
[90] Nor JE, Christensen J, Mooney DJ, Polverini PJ: Vascular Endothelial Growth Factor (VEGF)-
Mediated Angiogenesis is Associated with Enhanced Endothelial Cell Survival and Induction of 
Bcl-2 Expression. American Journal of Pathology 1999, 154(2):375-384. 
[91] Shibuya M: Differential Roles of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 
in Angiogenesis. Biochemistry and Molecular Biology International 2006, 39(5):469-478. 
[92] Taylor CR, Shi SR, Barr NJ: Chapter 1 - Techniques of Immunohistochemistry: Principles, 
Pitfalls, and Standardization. In: Diagnostic Immunohistochemistry (3rd Edition). Philadelphia: W.B. 
Saunders; 2011: 1-41. 
[93] Moreau A, Le Neel T, Truchaud A, Laboisse C: Approach to Automation in 
Immunohistochemistry. Clinica Chimica Acta 1998, 278:177-184. 
[94] Hayat MA: Chapter 1 - Comparison of Immunohistochemistry,in Situ Hybridization, 
Fluorescence in Situ Hybridization, and Chromogenic in Situ Hybridization. In: Handbook of 
 
 
 
 
93 
Immunohistochemistry and in Situ Hybridization of Human Carcinomas. San Diego: Academic Press; 
2004: 3-11. 
[95] Shi SR, Shi Y, Taylor CR: Antigen Retrieval Immunohistochemistry: Review and Future 
Prospects in Research and Diagnosis over Two Decades. Histochemistry and Cytochemistry 2011, 
59(1):13-32. 
[96] Attallah AM, El-Far M, Abdel CA, Zahran F, Farid K, Omran MM, Zagloul H, El-Deen MS: 
Evaluation of Cytokeratin-1 in the Diagnosis of Hepatocellular Carcinoma. Clinica Chimica Acta 
2011, 412(23–24):2310-2315. 
[97] Ramalho LNZ, Ribeiro-Silva A, Cassali GD, Zucoloto S: The Expression of p63 and Cytokeratin 5 
in Mixed Tumors of the Canine Mammary Gland Provides New Insights into the Histogenesis of 
These Neoplasms. Veterinary Pathology 2006, 43:424-429. 
[98] Lan Su D, Peter R, Morgan BDS, Lane BE: Expression of Cytokeratin Messenger RNA Versus 
Protein in the Normal Mammary Gland and in Breast Cancer. Human Pathology 1996, 27:800-
806. 
[99] Chu PG, Weiss LM: Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An 
Immunohistochemical Study of 509 Cases. Modern Pathology 2002, 15(1):6-10. 
[100] Raspollini MR, Fambrini M, Marchionni M, Baroni G, Taddei GL: In Situ Adenocarcinoma and 
Squamous Carcinoma of Uterine Cervix Pathological and Immunohistochemical Analysis with 
Cytokeratin 13. Obstetrics and Gynecology 2007, 134:249-253. 
[101] Ravindranath RMH, Tam W, Bringas P, Santos V, Fincham AG: Amelogenin-Cytokeratin 14 
Interaction in Ameloblasts during Enamel Formation. Biological Chemistry 2001, 276:36586-
36597. 
[102] Tse GMK, Tan PH, Lui PCW, Gilks CB, Poon CSP, Ma TKF, Law BKB, Lam WWM: The Role of 
Immunohistochemistry for Smooth-Muscle Actin, p63, CD10 and Cytokeratin 14 in the 
Differential Diagnosis of Papillary Lesions of the Breast. Clinical Pathology 2007, 60:315-320. 
[103] Harnden P, Southgate J: Cytokeratin 14 as a Marker of Squamous Differentiation in Transitional 
Cell Carcinomas. Clinical Pathology 1997, 50:1032-1033. 
[104] Se´guier S, Godeau  G, Leborgne M, Pivert G, Brousse M: Quantitative Morphological Analysis of 
Langerhans Cells in Healthy and Diseased Human Gingiva. Archives of Oral Biology 2000, 
45:1073-1081. 
[105] Jacobs JJL, Lehe C, Cammansa KDA, Yonedac K, Dasb PK, Elliotta GR: An Automated Method for 
the Quantification of Immunostained Human Langerhans Cells. Immunological Methods 2001, 
247:73-82. 
[106] Indrasingh I, Chandi G, Jeyaseelan L, Vettivel S, Chandi SM: Quantitative Analysis of CDIa (T6) 
Positive Langerhans Cells in Human Tonsil Epithelium. Annals of Anatomy 1999, 181:567-572. 
[107] Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, Sihto H, Laakkonen P, Heikkila¨ P, 
Joensuu H, Alitalo K: VEGFR-3 Expression Is Restricted to Blood and Lymphatic Vessels in Solid 
Tumors. Cancer Cell 2008, 13:554-556. 
 
 
 
 
 
 
94 
APPENDIXES 
APPENDIX I 
IMMUNOHISTOCHEMICAL STAINING PROTOCOL 
Table I: Chronological Instructions Followed During IHC Staining 
Step Brief Description 
 
Tissue Sectioning and Incubation 
 
Mount paraffin-embedded tissues 
Incubate overnight at 26°C 
Dewaxing Deparaffinize sections in Xylene for 5 minutes 
Place in decreasing grades of alcohol (100%, 96% and 70% ) for 2 minutes with 
each alcohol 
Rehydrate with distilled water for 2 minutes 
Antigen Retrieval Heat sections with the recommended unmasking solution (Citrate buffer, pH 6.0 
for 10-15 minutes; EDTA buffer, pH 9.0 for 10-15 minutes; Pepsin for 30 
minutes) 
Wash with PBS buffer 
Peroxidase Blocking Block sections using 3% hydrogen peroxide (H2O2) for 5 minutes 
Wash with PBS buffer 
Subsequent Blocking Block with normal rabbit serum (1:20 diluted) and drain off excess without 
washing 
Primary Antibody Incubation Incubate sections with primary antibody at room temperature for 30 minutes 
Wash with PBS buffer 
Biotinylated Secondary Antibody 
Incubation 
Incubate sections with Biotinylated Secondary Link antibody at room temperature 
for 30 minutes 
Wash with PBS 
Streptavidin-HPR Incubation Incubate sections with Streptavidin-HPR at room temperature for 30 minutes 
Wash with PBS buffer 
Chromogen Substrate Add a solution of substrate buffer and DAB to each section 
Incubate at room temperature for 10 minutes 
CuSO4 Addition  Incubate sections with CuSO4 at room temperature for 10 minutes  
Rinsing Rinse slides with water for 2 minutes 
Counterstaining Dip slides in Hematoxylin for 25 seconds 
Rinsing Rinse slides with water for 5 minutes 
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Dehydration Rehydrate the sections by immersing in increasing grades of alcohol (70%, 96% 
and 100%) 
Dip the sections in Xylene until clear 
Mounting of Sections Place DPX glue on the cover slips 
Place the stained sections over the cover slips 
Allow to air dry 
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APPENDIX II 
IMMUNOHISTOCHEMISTRY WASHING BUFFERS 
Table II: Different Concentrations of Phosphate Buffered Saline (PBS) 
Concentration of the buffer Measurement of the Constituents 
 
10X Working PBS (0.1 M PBS, pH 
7.2) 
 
Na2HPO4 (anhydrous) ………………………………………. 10.9 g 
NaH2PO4 (anhydrous) ………………………………………… 3.2 g 
NaCl …………………………………………………………… 90 g 
Distilled H2O …………………………………………….... 1000 ml 
20X Stock PBS Solution (0.2 M PBS, 
pH 7.2) 
Na2HPO4 (anhydrous) ……………………………………….. 21.8 g 
NaH2PO4 (anhydrous) ………………………………………… 6.4 g 
NaCl ………………………………………………………….. 180 g 
Distilled H2O …………………………………………….... 1000 ml 
Mix to dissolve the solution, adjust the pH to 7.2 using NaOH and HCl and 
store at room temperature. 
10X Working PBS – Tween 20 (0.1 M 
PBS, 0.5% Tween 20, pH 7.2) 
Na2HPO4 (anhydrous) ……………………………………….. 10.9 g 
NaH2PO4 (anhydrous) ………………………………………… 3.2 g 
NaCl …………………………………………………………… 90 g 
Distilled H2O ……………………………………………….. 1000 ml 
20X Stock PBS – Tween 20 Solution 
(0.2 M PBS, 1% Tween 20, pH 7.2) 
Na2HPO4 (anhydrous) ……………………………………….. 21.8 g 
NaH2PO4 (anhydrous) ………………………………………… 6.4 g 
NaCl ………………………………………………………….. 180 g 
Distilled H2O …………………………………………………1000 ml 
Mix to dissolve the solution, adjust the pH to 7.2 using NaOH and HCl. Add 
5 ml of Tween 20 and store at room temperature. 
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APPENDIX III 
ANTIGEN RETRIEVAL BUFFERS 
Table III: Constituents of the Unmasking Solutions used During IHC 
Antigen Retrieval Buffer Measurement of the Constituents 
 
Sodium Citrate Buffer (10 Mm Sodium 
Citrate, 0.05% Tween 20, pH 6.0) 
 
Tris-sodium citrate (dehydrate)……………………………… 2.94 g 
Distilled H2O ……..………………………………………... 1000 ml 
Mix well to dissolve. Adjust the pH to 6.0 with 1 N HCl, add 0.5 ml Tween 
20 and mix well. Store the solution at room temperature for up to 3 months 
or at 4ºC for longer usage. 
Citrate Buffer (10 Mm Citric Acid, 
0.05% Tween 20, pH 6.0) 
Citric acid (anhydrous) …………...…………………………. 1.92 g 
Distilled H2O ……..……………………………………….. 1000 ml 
Mix well to dissolve. Adjust the pH to 6.0 with NaOH, add 0.5 ml Tween 20 
and mix well. Store the solution at room temperature for up to 3 months or at 
4ºC for longer usage. 
Tris EDTA Buffer (pH 9.0) Tris (Hydroxymethyl) Aminomethane …………...………… 6.055 g 
EDTA (Ethylenediaminetetra acetic acid ……..……………… 1.86 g 
Distilled H2O ……..………………………………………. 5000 ml 
Mix well to dissolve. Adjust the pH to 9.0 with 0.1 M NaOH or 0.1 N HCl. 
Store the solution at 4ºC. 
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APPENDIX IV 
BLOCKING SOLUTIONS 
Table IV: Constituents of the Blocking Solutions used During IHC 
Blocking Solution Measurement of the Constituents 
 
Peroxidase Blocking Solution (3% 
H2O2 in PBS) 
 
30% H2O2 …………...……………………………………………2 ml 
1X PBS ……..……………………………………………….…..18 ml 
Mix well and store at 4ºC for up to 3 months. 
Peroxidase Blocking Solution (0.3% 
H2O2 in Methanol 
30% H2O2 …………...…………………………………………0.2 ml 
Methanol ……..……………………………………………..… 18 ml 
Mix well and store at 4ºC. 
Normal Rabbit Serum NCL-R-Serum …………...………………………………………1 ml 
PBS Buffer ……..……………………………………………… 19 ml 
Rabbit serum is used as a negative control or as a blocking reagent in IHC 
staining. It is also used as a ‘no primary’ antibody control. 
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APPENDIX V 
IMMUNOHISTOCHEMISTRY DILUENT SOLUTION 
Novocastra IHC diluent is used to dilute primary antibodies, Biotinylated secondary antibodies and 
Streptavidin-HPR in immunohistochemical staining procedures. 
Novocastra IHC Diluent – 500 ml  
MANUAL POLYMER DETECTION SYSTEM 
Biotinylated secondary antibody is applied for the detection of mouse IgG, mouse IgM and rabbit IgG primary 
antibodies. 
RE7103 Biotinylated secondary antibody – 25 ml 
Streptavidin-HPR is a streptavidin-cojugated horseradish peroxidase reagent. 
RE7104 Streptavidin-HPR – 25 ml 
Novolink DAB (polymer), RE7230-K is a two part DAB kit comprising of: 
RE7143 DAB Substrate buffer – 30 ml 
RE7105 DAB Chromogen – 3 ml 
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APPENDIX VI 
NOVOCASTRA™ LYOPHILIZED MOUSE MONOCLONAL ANTIBODIES 
Cytokeratin 1 
Product Code NCL-CK1 
Intended Use Research only 
Specificity Human cytokeratin 1 intermediate filament protein (68kD) 
Recommendations on Use IHC: Working dilution of 1:20 – 1:40, incubation at 25°C for 60 minutes 
Positive Controls IHC: Normal skin 
Staining Pattern Cytoplasmic 
Storage and Stability 
Store unopened at 4°C, product performance is maintained up to expiry date 
General Overview 
Present in complex epithelium; reacts with all squamous epithelium 
 
Cytokeratin 5 
Product Code NCL-CK5 
Intended Use In vitro diagnostic purposes 
Specificity Human cytokeratin 5 intermediate filament protein 
Recommendations on Use IHC: Working dilution of 1:100, incubation at 25°C for 30 minutes 
Positive Controls Prostate 
Staining Pattern Cytoplasmic 
Storage and Stability 
Store unopened at 2 - 8°C, product performance is maintained up to expiry date 
General Overview 
Present in the cytoplasm of many non-keratinized stratified squamous epithelia 
 
Cytokeratin 13 
Product Code  NCL-CK13 
Intended Use Research only 
Specificity Human cytokeratin 13 intermediate filament protein (54kD) 
Recommendations on Use IHC: Working dilution of 1:100 – 1:200, incubation at 25°C for 60 minutes 
Positive Controls IHC: Tonsil 
Staining Pattern Cytoplasmic staining of mucosa 
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Storage and Stability 
Store unopened at 4°C, product performance is maintained up to expiry date 
General Overview 
Expressed as a major component of squamous, non-keratinized epithelium, 
transitional epithelium, pseudostratified epithelium and myoepithelium 
 
Cytokeratin 14 
Product Code NCL-LL002 
Intended Use In vitro diagnostic purposes 
Specificity Human cytokeratin 14 intermediate filament protein 
Recommendations on Use IHC: Working dilution of 1:20, incubation at 25°C for 60 minutes 
Positive Controls IHC: Normal skin 
Staining Pattern Cytoplasmic 
Storage and Stability 
Store unopened at 2 – 8°C, product performance is maintained up to expiry date 
General Overview 
Stains the basal layer of stratified squamous and non-squamous epithelia 
 
Collagen IV 
Product Code NCL-COLL-IV 
Intended Use Research only 
Specificity Human collagen type IV 
Recommendations on Use IHC: Working dilution of 1:100 – 1:200, incubation at 25°C for 60 minutes 
Positive Controls IHC: Kidney, basement membranes 
Staining Pattern Basement membranes 
Storage and Stability 
Store unopened at 4°C, product performance is maintained up to expiry date 
General Overview 
Major constituent of basement membranes 
 
Laminin 
Product Code NCL-LAMININ 
Intended Use Research only 
Specificity Human laminin (850kD)  
Recommendations on Use IHC: Working dilution of 1:50 – 1:100, incubation at 25°C for 60 minutes 
Positive Controls IHC: Kidney, skeletal muscle, small intestine 
Staining Pattern Basement membranes of blood vessels, smooth muscle, ganglia and muscle fibers 
Storage and Stability 
Store unopened at 4°C, product performance is maintained up to expiry date 
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General Overview 
Organized within basement membranes such as those associated with epithelia, 
surrounding blood vessels, nerves and underlying pial sheaths of the brain 
 
Elastin 
Product Code NCL-ELASTIN 
Intended Use Research only 
Specificity Human insoluble elastin 
Recommendations on Use IHC: Working dilution of 1:100 – 1:200, incubation at 25°C for 60 minutes 
Positive Controls IHC: Kidney, small intestine, liver 
Staining Pattern Extracellular 
Storage and Stability 
Store unopened at 4°C, product performance is maintained up to expiry date  
General Overview 
Present in connective tissue and imparts the property of elasticity to vertebrate 
elastic tissue 
 
Fibronectin 
Product Code NCL-FIB 
Intended Use Research only 
Specificity Cell-attachment domain of human fibronectin 
Recommendations on Use IHC: Working dilution of 1:100 – 1:200, incubation at 25°C for 60 minutes 
Positive Controls IHC: Normal kidney 
Staining Pattern Extracellular staining of connective tissue matrix 
Storage and Stability 
Store unopened at 4°C, product performance is maintained up to expiry date 
General Overview 
Present in basement membranes and extracellular connective tissue matrix 
 
CD1a 
Product Code NCL-CD1a-235 
Intended Use In vitro diagnostic purposes 
Specificity Human CD1a molecule 
Recommendations on Use IHC: Working dilution of 1:15 – 1:30, incubation at 25°C for 60 minutes 
Positive Controls IHC: Normal skin 
Staining Pattern Staining of Langerhans cells 
Storage and Stability 
Store unopened at 2 - 8°C, product performance is maintained up to expiry date 
General Overview 
Stains Langerhans cells and dendritic cells of skin and tonsil 
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Vascular Endothelial Growth Factor Receptor 
Product Code NCL-L-VEGFR-3 
Intended Use Research only 
Specificity Human vascular endothelial growth factor receptor-3 
Recommendations on Use IHC: Working dilution of 1:50 – 1:100, incubation at 25°C for 60 minutes 
Positive Controls IHC: Placenta 
Staining Pattern Cytoplasmic 
Storage and Stability 
Store liquid antibody at 4°C, product performance is maintained up to expiry date 
General Overview 
Present in many tissues including lung, intestine, brain and placenta 
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APPENDIX VII 
STATISTICAL ANALYSIS DATA 
Table VII - a: Statistical Comparisons of Cytokeratin 1 Staining Intensity 
Parameter 
Table Analyzed Cytokeratin 1     
 
Friedman test       
P value < 0.0001     
Exact or approximate P value? Gaussian Approximation     
P value summary ****     
Are means signif. different? (P < 0.05) Yes     
Number of groups 4     
Friedman statistic 27.69     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT 20.50 Yes ** 
OVT vs OVT -3.500 No Ns 
OVT vs XVT 15.00 No Ns 
XVT vs OVT -24.00 Yes *** 
XVT vs XVT -5.500 No Ns 
OVTvs XVT 18.50 Yes ** 
 
 
Table VII - b: Statistical Comparisons of Cytokeratin 5 Staining Intensity 
Parameter 
Table Analyzed Cytokeratin 5     
 
Friedman test       
P value 0.0039     
Exact or approximate P value? Gaussian Approximation     
P value summary **     
Are means signif. different? (P < 0.05) Yes     
Number of groups 4     
Friedman statistic 13.35     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT 10.50 No ns 
OVT vs OVT -4.000 No ns 
OVT vs XVT 3.500 No ns 
XVT vs OVT -14.50 No ns 
XVT vs XVT -7.000 No ns 
OVTvs XVT 7.500 No ns 
 
 
Table VII - c: Statistical Comparisons of Cytokeratin 13 Staining Intensity 
Parameter 
Table Analyzed Cytokeratin 13     
 
Friedman test       
P value < 0.0001     
Exact or approximate P value? Gaussian Approximation     
P value summary ****     
Are means signif. different? (P < 0.05) Yes     
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Number of groups 4     
Friedman statistic 22.76     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT 15.00 No ns 
OVT vs OVT -1.500 No ns 
OVT vs XVT -1.500 No ns 
XVT vs OVT -16.50 Yes * 
XVT vs XVT -16.50 Yes * 
OVTvs XVT 0.0 No ns 
 
 
Table VII - d: Statistical Comparisons of Cytokeratin 14 Staining Intensity 
Parameter 
Table Analyzed Cytokeratin 14     
 
Friedman test       
P value 0.0003     
Exact or approximate P value? Gaussian Approximation     
P value summary ***     
Are means signif. different? (P < 0.05) Yes     
Number of groups 4     
Friedman statistic 18.55     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT 12.00 No ns 
OVT vs OVT -2.000 No ns 
OVT vs XVT -2.000 No ns 
XVT vs OVT -14.00 No ns 
XVT vs XVT -14.00 No ns 
OVTvs XVT 0.0 No ns 
 
 
Table VII - e: Statistical Comparisons of Collagen IV Staining Intensity 
Parameter 
Table Analyzed Collagen IV     
 
Friedman test       
P value 0.0049     
Exact or approximate P value? Gaussian Approximation     
P value summary **     
Are means signif. different? (P < 0.05) Yes     
Number of groups 6     
Friedman statistic 16.79     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT – h 12.50 No Ns 
OVT vs XVT – m 24.50 No Ns 
OVT vs OVT 6.500 No Ns 
OVT vs XVT - h 19.50 No Ns 
OVT vs XVT - m 24.00 No Ns 
XVT - h vs XVT – m 12.00 No Ns 
XVT - h vs OVT -6.000 No Ns 
XVT - h vs XVT - h 7.000 No Ns 
XVT - h vs XVT - m 11.50 No Ns 
XVT - m vs OVT -18.00 No Ns 
XVT - m vs XVT - h -5.000 No Ns 
XVT - m vs XVT - m -0.5000 No Ns 
OVTvs XVT - h 13.00 No Ns 
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OVTvs XVT - m 17.50 No Ns 
XVT - h vs XVT - m 4.500 No Ns 
 
Table VII - f: Statistical Comparisons of Laminin Staining Intensity 
Parameter 
Table Analyzed Laminin     
 
Friedman test       
P value 0.0004     
Exact or approximate P value? Gaussian Approximation     
P value summary ***     
Are means signif. different? (P < 0.05) Yes     
Number of groups 6     
Friedman statistic 22.59     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT – h 8.500 No ns 
OVT vs XVT – m 20.50 No ns 
OVT vs OVT 0.5000 No ns 
OVT vs XVT - h 11.50 No ns 
OVT vs XVT - m 25.00 Yes * 
XVT - h vs XVT – m 12.00 No ns 
XVT - h vs OVT -8.000 No ns 
XVT - h vs XVT - h 3.000 No ns 
XVT - h vs XVT - m 16.50 No ns 
XVT - m vs OVT -20.00 No ns 
XVT - m vs XVT - h -9.000 No ns 
XVT - m vs XVT - m 4.500 No ns 
OVTvs XVT - h 11.00 No ns 
OVTvs XVT - m 24.50 No ns 
XVT - h vs XVT - m 13.50 No ns 
 
 
Table VII - g: Statistical Comparisons of Elastin Staining Intensity 
Parameter 
Table Analyzed Elastin     
 
Friedman test       
P value 0.0020     
Exact or approximate P value? Gaussian Approximation     
P value summary **     
Are means signif. different? (P < 0.05) Yes     
Number of groups 4     
Friedman statistic 14.78     
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT -5.000 No ns 
OVT vs OVT -14.50 No ns 
OVT vs XVT -12.50 No ns 
XVT vs OVT -9.500 No ns 
XVT vs XVT -7.500 No ns 
OVTvs XVT 2.000 No ns 
 
 
Table VII - h: Statistical Comparisons of Fibronectin Staining Intensity 
Parameter 
Table Analyzed Fibronectin     
 
Friedman test       
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P value < 0.0001     
Exact or approximate P value? Gaussian Approximation     
P value summary ****     
Are means signif. different? (P < 0.05) Yes     
Number of groups 6     
Friedman statistic 47.27     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT – h 11.50 No ns 
OVT vs XVT – m 19.50 No ns 
OVT vs OVT -16.50 No ns 
OVT vs XVT - h -16.50 No ns 
OVT vs XVT - m 23.00 No ns 
XVT - h vs XVT – m 8.000 No ns 
XVT - h vs OVT -28.00 Yes * 
XVT - h vs XVT - h -28.00 Yes * 
XVT - h vs XVT - m 11.50 No ns 
XVT - m vs OVT -36.00 Yes *** 
XVT - m vs XVT - h -36.00 Yes *** 
XVT - m vs XVT - m 3.500 No ns 
OVTvs XVT - h 0.0 No ns 
OVTvs XVT - m 39.50 Yes *** 
XVT - h vs XVT - m 39.50 Yes *** 
 
 
Table VII - i: Statistical Comparisons of Langerhans Cells Staining Intensity 
Parameter 
Table Analyzed Langerhans Cells     
 
Friedman test       
P value < 0.0001     
Exact or approximate P value? Gaussian Approximation     
P value summary ****     
Are means signif. different? (P < 0.05) Yes     
Number of groups 6     
Friedman statistic 40.55     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT – h 9.500 No Ns 
OVT vs XVT – m 25.00 Yes * 
OVT vs OVT -11.50 No Ns 
OVT vs XVT - h 21.00 No Ns 
OVT vs XVT - m 28.00 Yes * 
XVT - h vs XVT – m 15.50 No Ns 
XVT - h vs OVT -21.00 No Ns 
XVT - h vs XVT - h 11.50 No Ns 
XVT - h vs XVT - m 18.50 No Ns 
XVT - m vs OVT -36.50 Yes *** 
XVT - m vs XVT - h -4.000 No Ns 
XVT - m vs XVT - m 3.000 No Ns 
OVTvs XVT - h 32.50 Yes ** 
OVTvs XVT - m 39.50 Yes *** 
XVT - h vs XVT - m 7.000 No Ns 
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Table VII - j: Statistical Comparisons of VEGFR Staining Intensity 
Parameter 
Table Analyzed VEGFR     
 
Friedman test       
P value 0.0012     
Exact or approximate P value? Gaussian Approximation     
P value summary **     
Are means signif. different? (P < 0.05) Yes     
Number of groups 6     
Friedman statistic 20.00     
 
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
OVT vs XVT – h 12.00 No ns 
OVT vs XVT – m 15.00 No ns 
OVT vs OVT 15.00 No ns 
OVT vs XVT - h 15.00 No ns 
OVT vs XVT - m 15.00 No ns 
XVT - h vs XVT - m 3.000 No ns 
XVT - h vs OVT 3.000 No ns 
XVT - h vs XVT - h 3.000 No ns 
XVT - h vs XVT - m 0.0 No ns 
XVT - m vs OVT 0.0 No ns 
XVT - m vs XVT - h 0.0 No ns 
XVT - m vs XVT - m 0.0 No ns 
OVTvs XVT - h 0.0 No ns 
OVTvs XVT - m 0.0 No ns 
XVT - h vs XVT - m 0.0 No ns 
 
 
 
 
 
 
